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REGULATION OF VANCOMYCIN RESISTANCE  
 
AND STRESS RESPONSE BY THE MSAABCR  
 
OPERON IN STAPHYLOCOCCUS AUREUS 
 
by Dhritiman Samanta 
August 2015 
Staphylococcus aureus is the predominant cause of public health problems around 
the world. Vancomycin has been an important antibiotic against Methicillin Resistant 
Staphylococcus aureus (MRSA) infections. However, Vancomycin Intermediate S. 
aureus (VISA) strains have been reported. These strains are characterized by thick cell 
walls, reduced autolytic rate, reduced PBP4 activity, and increased amount of D-Ala-D-
Ala termini in the cell wall. In this study, we show that the msaABCR operon regulates 
vancomycin resistance in two clinical VISA strains. Deletion of the msaABCR operon in 
strains Mu50 and HIP6297 resulted in a significant decrease in the minimum inhibitory 
concentration (MIC) for vancomycin. Transmission Electron Microscopic analysis 
showed a 50% decrease in the cell wall thickness in the mutants relative to wild types. 
The msaABCR mutant of Mu50 but not HIP6297 showed a 3-fold up-regulation of pbp4. 
Up-regulation of pbp4 was confirmed by fluorescent penicillin–binding assay, which 
showed that the mutant has a 6-fold higher amount of PBP4 protein relative to wild type. 
Mu50 msaABCR mutant also showed a 6-fold down-regulation of stress response 
regulator sigB. On the other hand, the msaABCR mutant of HIP6297 showed a 4-fold 
down-regulation of mprF. Collectively, my data show that the msaABCR is required for 
maintaining the thickness of cell wall and vancomycin resistance in two clinical VISA 
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strains Mu50 and HIP6297; however, the mechanism and regulation by the msaABCR 
operon in the genetic level are strain dependent.  
Staphylococcus aureus is also the predominant cause of bacteremia worldwide. 
The health hazard burden caused by this species is severely exacerbated by worldwide 
dissemination of clones resistant to beta-lactam antibiotics in hospitals and communities. 
The distribution of MRSA clones is dynamic and tends to be geographically unique. The 
purpose of the second part of my study is to determine the molecular characteristics and 
antibiotic resistance properties of the MRSA isolates causing bacteremia in a major 
hospital in south Mississippi, USA. This study allows us to associate specific clonal types 
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The Biology of Staphylococcus aureus 
Staphylococcus aureus (S. aureus) is a Gram - positive coccus bacterium 
belonging to the phylum Firmicutes, class Bacilli, and order Bacillales.  This coagulase 
positive coccus, measuring about 0.7 – 1.2 µm in diameter, is much studied because of its 
clinical importance to human. Although S. aureus normally resides in the nose, throat, 
armpit, groin, and intestinal tract of healthy individuals, when introduced into a wound or 
skin incision, cause infections. According to the Center for Disease Control and 
Prevention (CDC), S. aureus is the most common cause of hospital-acquired infections 
causing 80,461 invasive MRSA infections including 11,285 deaths in USA. Tremendous 
amount of resources have been used to understand the molecular basis of its virulence 
and evolutionary success using modern technology. An in depth understanding of its 
global regulatory network is necessary to fully decipher its array of virulence factors and 
to devise mechanism to control it.  
The term “staphylococcus” was synthesized from the Greek word “staphyle,” 
which means bunch of grapes and the term “coccus” meaning grain or berry, because of 
its clustered appearance under microscope. Robert Koch, in 1878 first identified that 
abscesses are caused by Gram-positive cocci. Later in 1884, Rosenbach classified species 
of staphylococci depending on their capability of producing pigments, where more 
virulent species formed golden colonies whereas less pathogenic ones formed white 
colonies. Coagulase testing later proved to be a better classification of staphylococci than 









Figure 1.1. A representative image of S. aureus under microscope. Characteristic 
clumping behavior is evident in this figure. (Photo Credit: Janice Haney Carr, Center for 
Disease Control and Prevention) 
S. aureus grows most rapidly under aerobic conditions and in the presence of 
carbon-di-oxide. However, S. aureus is also capable of surviving in environments with 
very low concentrations of oxygen as well, such as within a biofilm (1). It is versatile in 
terms of tolerating extreme conditions. For example it can tolerate high amounts of salt in 
growth medium (7.5 – 10% of Sodium Chloride) (2) and a wide pH range (4.8 – 9.4).  
 S. aureus colonizes human body in early years of life and is carried throughout 
the life. 30% of United States population carry S. aureus in the nasal passage (3, 4). It 
adheres to nasal mucosal surface with the help of several virulence factors such as surface 
protein adhesins, fibronectin – binding protein, and clumping factor (5-8). A large variety 
of proteins and carbohydrates expressed on the cell surface enables S. aureus to bind to a 
number of host factors such as epithelial cells, endothelial cells, platelets, and host 
intercellular matrix proteins (9). Penicillin, once was used to treat S. aureus infections. 
However, as S. aureus got resistant to it, methicillin, a penicillin derivative was 
introduced. S. aureus, however acquired resistance against methicillin quickly. Rise of 




health worldwide. MRSA causes about 1,20,000 hospitalizations and more than 1 billion 
dollars healthcare costs in the U.S.. Initially, MRSA strains were largely confined to 
hospitals and were referred to as hospital-acquired MRSA (HA-MRSA), causing 
treatment difficulties, especially in patients with prior exposure to antibiotics. During the 
past two decades, S. aureus infections have been worsened by the emergence of 
community-acquired MRSA (CA-MRSA). The United States, in particular has been 
facing an epidemic caused by CA-MRSA isolates. CA-MRSA isolates are clinically 
significant because they can also cause severe health issues in individuals who are 
apparently healthy and have never been exposed to any predisposing risk factors. It is 
imperative that new therapeutic solutions are found for this rapidly evolving pathogen. 
Staphylococcus aureus is a multifaceted pathogen that causes a wide array of 
infections ranging from simple skin abscesses to more complex and life threatening 
conditions like endocarditis and osteomyelitis. Other serious conditions caused by S. 
aureus include S. aureus bacteremia (SAB), S. aureus infective endocarditis (SAIE), 
surgical site infections, device related infections (catheters, implants etc.), skin and soft 
tissue infections (SSTIs), spine and brain abscesses, ocular diseases, staphylococcal 
pneumonia, urinary tract infections, toxic shock syndrome, and toxin mediated 
syndromes. S. aureus is able to cause these infections by successfully utilizing an array of 
virulence factors. These factors are often redundant and/or variable across different 










Figure 1.2. A. Endocarditis and B. Osteomyelitis.  Photo credit: Center for Disease 
Control and Prevention) 
Antibiotic Resistance in Staphylococcus aureus 
Treatment of S. aureus has become more difficult attributable to the profuse 
increase in prevalence of MRSA strains in the last few decades. Particularly, CA-MRSA 
strains are of great concern because of their capability of causing wide variety of 
infections, high growth rate, and causing diseases in people without any risk factors. CA-
MRSA strains cause skin and soft tissue infections, which spreads from skin to skin 
contact with infected individuals. Interestingly, CA-MRSA is resistant to only β-lactams 
and only a few other classes of antibiotics, however, HA-MRSA is resistant to multiple 
types of antibiotics (10). The antibiotic resistance profile of MRSA strains is partly due to 
the presence of resistance genes that are located in a mobile genetic element called 
Staphylococcal cassette chromosome mec (SCCmec). The methicillin resistance of S. 
aureus is the result of the presence of the mecA gene, which encodes a 78-kDa penicillin-
binding protein (PBP2a or PBP2′). S. aureus possesses four types of penicillin binding 
proteins, which are essential enzymes for synthesis of cell wall. The β-lactam antibiotics 
such as penicillin and methicillin bind to PBP2 and inhibits cell wall synthesis process.  
PBP2a, produced by mecA gene in MRSA strains has a lower affinity for the β-lactam 





synthesis is not disrupted and the bacterium survives (11, 12). The mecA gene is housed 
within the mec operon along with the regulatory genes mecI and mecR1 (11). Since the 
first detection of the SCCmec element from N315 in 1999, multiple mec types have been 
identified because of the hypervariability of SCCmec elements. Nine SCCmec types (I–
VIII and VT) have been detected to date. These are distinguished by the ccr gene complex 
which helps in excision and insertion of SCCmec elements (13-15). Clones of unique 
SCCmec types have driven the epidemic of MRSA strins worldwide. For example, 
SCCmec type I was first discovered in the United Kingdom in 1961 and spread around 
the world during the ’60s. Following that, in 1982, SCCmec type II was first identified in 
Japan also spread worldwide. During the 1990s SCCmec type IV caused a global 





Figure 1.3. Different types of SCCmec elements distinguished by ccr gene complex and 






BACKGROUND RELEVANT TO THIS STUDY 
Cell Wall Synthesis and Vancomycin Resistance in  
Staphylococcus aureus 
The glycopeptide antibiotic vancomycin has been used to successfully treat 
MRSA infections. Increasing prevalence of MRSA resulted in excessive use of 
vancomycin thereby increasing the selective pressure, which leads to the development of 
resistance. The first clinical strain that was reported to be vancomycin resistant was 
Mu50, which was isolated in 1997 from a Japanese male patient who had been under 
vancomycin treatment for prolonged period of time before the strain was isolated. 
Subsequently, there have been reports of similar strains being isolated from other parts of 
the world.  
The mechanism of intermediate vancomycin resistance seems novel. Many of the 
vancomycin non–susceptible strains tested have been found negative for van gene 
complex that confer vancomycin resistance in enterococci. Although there are phenotypic 
variations among the vancomycin non-susceptible strains from different parts of the 
world, the most common characteristic feature is a very thick cell wall. Increase in cell 
wall synthesis has been reported from both the clinical and laboratory-generated strains.  
Vancomycin targets the D-ala-D-ala subunits of the peptidoglycan leading to cell 
death by inhibiting cell wall crosslinking. It is important to understand the cell wall 
synthesis in order to fully understand the action of vancomycin and how the bacterium 
resists it. Walsh et al (16) described the process as following. S. aureus cell wall is 




β-1,4-linked chains containing alternating subunits of N-acetylglucosamine (GlcNAc) 
and N-acetylmuramic acid (MurNac). Biosynthesis of glucosamine-1-phosphate from 
glucose and/or glucosamine initiates the process of peptidoglycan synthesis. Pyrimidine 
UDP is then linked to glucosamine-1-phosphate to produce UDP-N-acetyl-glucosamine 
(UDP-GlcNAc). A second molecule of UDP-GlcNAc combines with phosphoenol 
pyruvate, which is produced from glucose in glycolysis to form UDP-N-acetyl-muramic 
acid (UDP-MurNAc). An L-alanine is then linked to the UDP-MurNAc residue followed 
by D-glutamate, L-lysine, and D-alanyl-D-alnine to form the UDP-MurNAc 
pentapeptide. It is then transferred to the C55-undecaprenylphosphate to form LIPID-I of 
the cytoplasmic membrane peptidoglycan transporter. Next step is the formation of 
pentaglycine side chain on the L-lysine component. The D-glutamate component is then 
amidated to D-glutamine using an L-glutamine, which acts as a NH4
+
 donor. This 
complex is then transferred to the outside of the cell. It is then joined to the nascent 
peptidoglycan chain by the activity of transglycosylase enzymes, which links the moieties 
Glc-NAc-MurNAc –pentapeptide-pentaglycine. Transpeptidase enzymes then join the 
pentaglycine chain of one monomer to the penultimate D-Ala residue of the pentapeptide 
of the next peptidoglycan chain, releasing the last D-Ala residue. This cleavage of the last 
D-Ala residue is a key step to the cell wall crosslinking process. Although theoretically 
all D-Ala-D-Ala residues should be digested in the process, approximately 20% of them 
remain intact. Vancomycin binds to the D-Ala-D-ala residue of the peptidoglycan 
precursor UDP-MurNAc-pentapeptide and inhibit transpeptidation and nascent 




Vancomycin non-susceptible strains have been found to possess an increased cell 
wall synthesis coupled with reduced crosslinks in the peptidoglycan. It is proposed that 
reduced levels of peptidoglycan crosslinking leads to an increased amount of intact D-
Ala-D-ala side chains to which vancomycin can bind. The main location of cell wall 
synthesis in S. aureus is the tip of the division septum of a bacterium and not the entire 
plasma membrane surface (17). Therefore, in order for vancomycin to prevent cell wall 
synthesis, it would have to diffuse through the cell wall to the tip of the division septum, 
which is approximately a 25-nm path (18). The D-Ala-D-Ala-vancomycin complex in the 
outer edges of the peptidoglycan are likely to sterically hinder the other vancomycin 
molecules preventing its diffusion from the environment to the cell’s active site, which is 
the tip of the division septum in the cytoplasmic membrane (19, 20). This enables 
vancomycin non-susceptible strains to continue synthesizing peptidoglycan and to 
survive in a vancomycin-containing environment.  
Stress response regulator genes, such as sigma B, have been found to regulate 
antibiotic resistance in S. aureus. Cold shock is one of the stress factors that bacteria may 
encounter. Designated cold shock proteins (CSPs) respond to the environment and induce 
the expression of necessary genes to keep bacterial cells alive. MsaB protein (previously 
called Cold shock protein A) of S. aureus is predicted to contain a cold shock DNA 
binding domain (CSD) and bears homology to E. coli and B. subtilis cold shock proteins 
(CSPs).  Bacteria respond to abrupt decrease in temperature by changing the protein 
expression patterns (21). Although expression of most cellular proteins decrease during 
the cold stress, expression of cold shock proteins reaches its peak at this time. One of the 




(22). Although most CSPs are found to be expressed during cold shock, CspE and CspC 
are found to express constitutively at normal growth conditions at 37°C. Moreover, the 
constitutively expressed CSPs were thought to be regulating two major stress response 
proteins of E. coli RpoS and UspA (23). In the last chapter of my dissertation, I 
investigated the role of msaB gene and MsaB protein in survival of S. aureus in stress 
environment. 
 
Figure 2.1. Model of mechanism of action of vancomycin that binds to the lipid II of 
peptidoglycan precursor and blocks the downstream pathway of cell-wall biosynthesis. 







THE msaABCR OPERON REGULATES RESISTANCE IN  
VANCOMYCIN-INTERMEDIATE Staphylococcus aureus STRAINS 
Abstract 
Vancomycin-intermediate Staphylococcus aureus (VISA) strains poses a serious 
public health threat. The molecular mechanism responsible for this resistance is not yet 
completely understood. In this part of my study, I investigate the role of the newly 
discovered msaABCR operon in establishing vancomycin resistance in three clinical 
VISA strains, Mu50, HIP6297, and LIM2. Deletion of the msaABCR operon resulted in a 
significant decrease in the vancomycin MIC (from 6.25 to 1.56 µg/mL) and a significant 
reduction of cell wall thickness in all three VISA strains. Mutants exhibited a 
significantly slower growth in medium containing vancomycin, at a concentration greater 
than 2 µg/ml, compared with the wild-type strain. Mutants also revealed significantly less 
capability to bind vancomycin molecules in medium compared to wild type. From this 
study, I conclude that the msaABCR operon in S. aureus strains contributes to resistance 
against vancomycin and cell wall synthesis. 
Introduction 
Staphylococcus aureus is an important public health pathogen in both community 
and healthcare settings. S. aureus can cause wide range of infections that can be 
superficial (e.g., skin and soft tissue infections) or life threatening (e.g., toxic shock, 
endocarditis, and septicemia) (24). One of the key attributes of S. aureus as a pathogen is 
the acquisition of antibiotic resistance, as evidenced by the rise and widespread 




community-acquired MRSA strains that are more virulent compared to other strains has 
worsened the situation (25, 26). Indeed, since the 1990s, MRSA strains have been 
responsible for one third of all S. aureus infections worldwide (27). Vancomycin, a 
glycopeptide antibiotic has been the drug of choice to treat MRSA infections for a long 
time (24). However, vancomycin non-susceptibility in S. aureus is becoming increasingly 
prevalent. 
Vancomycin-resistant S. aureus strains have been categorized into two major 
groups depending on their level of resistance, as measured by the minimum inhibitory 
concentration (MIC). According to the Clinical Laboratory Standards Institute (CLSI), S. 
aureus strains are considered sensitive if their MIC of vancomycin is less than or equal to 
2 µg/ml. Strains are called vancomycin-intermediate S. aureus (VISA) if their MIC 
ranges from 4 to 8 µg/ml, while strains that show a vancomycin MIC higher than 16 
µg/ml are classified as vancomycin-resistant S. aureus (VRSA). The prevalence of the 
VRSA strains is very low compared to VISA strains, which are more frequently 
encountered (28) 
First report of VISA strains came from a hospital in Japan in 1997 and since then 
these strains have emerged as a serious threat to public health owing to the extensive use 
of vancomycin in healthcare settings (29). Since then, several MRSA strains with 
intermediate-level resistance to vancomycin have been isolated from all over the world 
(30-38). In clinical settings, patients infected by VISA strains tend to have several co-
morbidities like diabetes mellitus, end-stage renal disease, or cancer; and usually have 




detection of VISA. Additionally, infections also can occur in biomedical devices such as 
catheters and transplants and they do not respond well to vancomycin treatment (16).  
Despite a number of studies performed by several people, the mechanism of 
vancomycin intermediate resistance is not completely understood. As mentioned before, 
vancomycin targets the cell wall and inhibits its synthesis by attaching to D-Ala-D-Ala 
residues of pentapeptide sidechain of undecaprenylphosphate-MurNAc-pentapeptide. 
Multiple genetic and biochemical mechanisms have been found to play together to 
establish the VISA phenotypes. These include: a thickened cell wall (39), reduced 
autolytic activity (40), increased proportion of non-amidated muropeptides (41), and 
reduced cross-linking between murein monomers caused by down-regulation of 
penicillin-binding protein 4 (PBP4) (42, 43), which ultimately leads to an accumulation 
of D-Ala-D-Ala pseudo-targets in the cell wall (20). Moreover, several genes have been 
found to be altered in expression in VISA strains. These include genes like atl (major 
autolysin), lytM (peptidoglycan hydrolase) (40), sceD (transglycosylase) (44), mprF 
(lysyl-phosphatidyl glycerol) (45), dltA (teichoic acid biosynthesis regulator), sigB (46-
49), ddh (50, 51), tcaA (52), and two-component systems graSR, vraSR, and walKR (53). 
Yet, we do not fully understand how S. aureus strains avert the effects of vancomycin. 
However, from all these studies, it is clear that resistance to vancomycin is significantly 
more complex than what we have thought about it so far.  
Previously, our lab has identified and characterized the msaABCR operon and 
shown that it positively regulates expression of a global regulator gene sarA, 
development of biofilm, and virulence of S. aureus strains(54-56). The msaABCR operon 




which are all in same orientation, and newly discovered msaR antisense RNA which is in 
opposite orientation (56). One of the most important phenotypes observed in the 
msaABCR operon mutant was increased triton-X–induced autolysis rate (Figure 3.1). A 
reduced rate of autolysis has been previously correlated with vancomycin-intermediate 
resistance (40, 57). Although the mechanism unclear, some studies have suggested that 
reduced autolysis indeed leads to resistance against multiple cell-wall active antibiotics 
(58). Also, inactivation of the sarA has been shown to lead to a decrease in the 
vancomycin MIC of laboratory-derived VISA strains (59). These findings led me to 
investigate the role of the msaABCR operon in the establishment of vancomycin 
intermediate resistance phenotype of S. aureus, and indeed our results show that the 
msaABCR operon contributes significantly vancomycin resistance in three different 
clinical VISA strains, Mu50, HIP6297 and LIM2. 
Materials and Methods 
Bacterial strains and culture conditions 
Wild type and mutant strains of S. aureus are listed in Table 3.1. Escherichia coli 
strain TOP10 (Life Technologies, New York, USA) was used for molecular cloning 
experiments. Luria-Bertani medium was used for E. coli culture. Brain-heart infusion 
(BHI) broth and agar were routinely used for culturing all VISA strains unless otherwise 
mentioned. Tryptic soy broth and agar were used for culturing S. aureus strain RN4220. 
For maintaining plasmids, appropriate antibiotics were added to the media at a 
concentration of 100 µg/mL of ampicillin for E. coli and 10 µg/mL of chloramphenicol 





Generation of the deletion mutants and complementation 
All plasmids and primers used in this study are listed in Table 3.2. Isogenic 
deletion mutants of the msaABCR operon were generated in the VISA Mu50, HIP6297, 
and LIM2 strains using the plasmid pKOR1, as described previously (60). Briefly, 
approximately 1 kb of sequence up- and downstream of the operon region was PCR 
amplified with operon deletion primers (Operon del 1 through 4). The PCR products were 
digested with restriction enzyme BamHI and ligated. The ligation product was amplified 
again with the terminal AttB-containing operon deletion primers (Operon del 1 and 4) 
and recombined into pKOR1 using the BP Clonase Kit (Life Technologies) resulting in 
pKOR1∆msaABCR. This plasmid was introduced into S. aureus RN4220 by 
electroporation. The constructs were subsequently transduced into strains Mu50, 
HIP6297 and LIM2 using bacteriophage φ. Mutagenesis was performed using the method 
described by Bae and Schneewind, 2006 (60). The mutation was confirmed by PCR using 
terminal primers.  
For trans-complementation, a low copy number plasmid pCN34 was used (61). 
To replace the kanamycin (aphA-3) selection marker of pCN34 with a chloramphenicol 
marker, the cat gene was PCR amplified from pHV1249 (62) using the primers Cm-F and 
Cm-R to generate an ApaI–XhoI fragment, which was then cloned into pCN34 resulting 
in plasmid pCN34(Cm
r
). A 1.7-kb BamHI and EcoRI fragment was then PCR amplified 
using the primers Comp-F1 and Comp-R1 from the genomic DNA of S. aureus strain 
Mu50/HIP6297/LIM2 and cloned into pCN34(Cm
r
) generating the pCN34(Cm
r
)–
msaABCR operon. This plasmid was introduced into S. aureus strain RN4220 by 




Complemented strains were always maintained in media containing 10 µg/mL of 
chloramphenicol.  
Triton X-100 induced autolysis 
Autolysis assay was performed as described by Mani et al, 1993 (63). Briefly, 
overnight cultures were normalized to OD600 = 0.05 in BHI containing 1M NaCl. Cells 
were harvested when they reach OD600 = 0.7, resuspended in autolysis buffer (Tris-HCl 
pH=7.5, 0.05% triton X-100) and incubated in 37°C. OD600 was recorded each hour.   
Vancomycin susceptibility assay 
Antimicrobial susceptibility of all strains was measured in triplicate by the broth 
microdilution method according to the CLSI guidelines (64). Mueller-Hinton broth 
supplemented with 2% NaCl (CSMHB) was used for all broth microdilution experiments. 
Antimicrobial containing wells were inoculated with 5 × 10
5 
CFU/mL (65). After 
overnight incubation at 35°C, wells were analyzed for visible bacterial growth as 
exhibited by turbidity. The lowest concentration of vancomycin that prevented bacterial 
growth was considered to be the MIC.  
Growth curve 
An aliquot of fresh bacterial culture was diluted to about 1 × 10
5 
CFU/mL in 25 
mL of fresh BHI broth and grown at 37°C with shaking. The optical density was 
measured at 600 nm at time intervals. To analyze the growth defect of the msaABCR 
operon mutants in vancomycin containing media, BHI supplemented with vancomycin at 
a concentration of 1, 2, and 3 µg/mL was used. For replenishment of the medium in 
experiments plotting prolonged growth curves, vancomycin at a concentration of 4 




Population analysis profile 
Population analysis helps to determine how many cells within a given number of 
cells are resistant to a range of concentrations of a particular antibiotic (39). Overnight 





 and 100 µL of each dilution were plated onto BHI agar plates 
containing various concentration of vancomycin. Plates were incubated for 48 h at 37°C, 
and CFUs were plotted in a logarithmic scale against the vancomycin concentration. 
Transmission electron microscopy 
Preparation and examination of S. aureus cells by transmission electron 
microscopy were performed by the method described previously (66). Briefly, 
exponentially growing cells were fixed in 2% glutaraldehyde in 0.1 M sodium phosphate 
buffer and treated with 1% osmium tetroxide for 2 h at 4°C. Cells were dehydrated, and 
embedded in low viscosity embedding media (Electron Microscopy Sciences). Ultra-thin 
sections were stained with uranyl acetate and lead acetate. Cell wall thicknesses were 
measured using photographic images at a ×30,000 final magnification. Fifteen cells of 
each strain with approximately equatorial cut surfaces were measured and results were 
expressed as the mean value ± standard deviation (SD). Statistical analysis was 
performed using the MedCalc software (MedCalc V13, www.medcalc.org). P value less 
than 0.05 was considered significant.  
Vancomycin binding assay 
The degree of binding of vancomycin molecules to the cell wall of wild-type 
strains and their respective msaABCR operon deletion mutants was determined using a 




BHI medium containing no antibiotics. When the cells reached the mid log phase, 
vancomycin was added at a concentration of 4 µg/mL to the culture. After 1 h, 500 µL of 
culture was collected and centrifuged to pellet the cells. Then, 10 µL of the supernatant 
was loaded onto a nitrocellulose membrane and air-dried. The membrane was then 
blocked with non-fat skimmed milk, incubated with an anti-vancomycin primary 
antibody, HRP-conjugated secondary antibody, and developed with SuperSignal
®
 West 
Pico Chemiluminescent substrate (Thermo Scientific, Rockford, Illinois, USA). The 
intensity of the signal was measured using the ImageJ software (67)   
RNA extraction, reverse transcription, and qRT-PCR 
An aliquot of an overnight culture was normalized to OD600 = 0.05 and grown to 
exponential phase. At this time, a dose of 4 µg/mL of vancomycin was added to the 
culture. A control culture was maintained where no vancomycin was added (“none” 
condition). Cells were grown for 1 h and harvested by centrifugation. The bacterial pellet 
was treated with RNAprotect
TM 
Bacteria Reagent (Qiagen, Valencia, CA, USA) and 
stored at −80°C. RNA from the pellet was isolated using the RNeasy
®
 mini kit (Qiagen) 
and dissolved in DEPC-treated H2O. RNA quality was analyzed by determining the 
A260/280 ratio using a nanodrop spectrophotometer (Thermo). Reverse transcription was 
carried out from 1000 ng of RNA using the iScript
TM
 cDNA synthesis kit (Bio-Rad 
Laboratories, Hercules, CA, USA) according to the manufacturer’s instructions. All real-
time PCRs were performed in triplicate. The primers used for real-time PCR are listed in 
Table 3.2. The fold change in gene expression was calculated using the formula 2
-∆∆ct  
(68), using the gyrA gene as an internal control. Fold change values were statistically 




Absolute quantification of the sigB transcript 
Absolute quantification of the sigB transcript was performed by the method 
previously described by Chini et al. 2007 (69). Briefly, the sigB and gyrA genes were 
amplified from chromosomal DNA using primers external to the primers used for qRT-
PCR. These amplicons were purified, and their concentrations were measured using a 
nanodrop spectrophotometer. The corresponding concentration was converted to copies 





) of these amplicons were used as templates for qRT-PCR. Standard curves were 
generated by plotting Ct values against the log of the copy numbers (Log Starting 
Quantity, SQ). Starting quantities of “unknown” samples (cDNA of wild type and 
mutant) were calculated by plotting their respective Ct values on the standard curve. Copy 
numbers were measured by raising 10 to the power of the SQ (10
SQ
). Copy numbers of 
sigB were normalized to that of gyrA and plotted. The process was repeated in triplicate 
independently. 
Membrane purification and PBP detection 
For the detection of PBPs, membranes were prepared from wild-type and 
msaABCR mutant strains following the method described by Sieradzki et al. 1999 (36), 
with some modifications. Briefly, cells were grown to the late exponential phase, 
harvested, and washed once with wash buffer (50 mM Tris, 150 mM NaCl, 5 mM MgCl2, 
pH 7.5), resuspended in the same buffer with 0.5 mM phenylmethylsulfonyl fluoride and 
10 mM β-mercaptoethanol. Cells were then treated with lysostaphin (100 µg/mL), DNase 
(20 µg/mL), and RNase (10 µg/mL) for 30 min on ice followed by sonication. Broken 




at 4°C, and washed with 50 mM phosphate buffer, pH 7. Membranes were solubilized in 
2% Triton X-100. Protein concentrations were measured using the BCA protein assay kit 
(Pierce) and a standard curve prepared from serial dilutions of bovine serum albumin.  
PBPs were detected using a method described by Atilano et al. 2010 (71), with 
some modifications. Briefly, 10 µg of membrane protein were mixed with 100 µM of 
Bocillin-FL (Life Technologies) and incubated for 10 min at 30°C. The reaction was 
stopped by the addition of 5× SDS-PAGE sample buffer. Samples were separated on a 4–
20% gradient gel and labeled proteins were detected using a Bio-Rad Versadoc. The gel 
pictures were analyzed and quantified using the ImageJ software.  
Results and Discussion 
Deletion of the msaABCR operon increased susceptibility to vancomycin in three VISA 
strains 
Several studies have demonstrated that global regulators such as sarA and sigB 
are involved in vancomycin resistance (59, 72); however, the mechanism of regulation is 
not yet understood (47, 73). Because msaABCR is a positive regulator of sarA and a 
negative regulator of autolysis, and as mentioned earlier, both the expression of sarA and 
a decreased rate of autolysis have been shown to be important for the VISA phenotype, 
we attempted to understand the effect of the msaABCR operon on vancomycin resistance 





Figure 3.1. Triton X-100 induced autolysis assay shows msaABCR mutants lyse in a 
faster rate than the respective wild types 
We deleted the msaABCR operon in three different clinical VISA strains, Mu50 
(SCCmec II, ST 5) and HIP6297 (SCCmec II, ST5) and LIM2 (SCCmec I, ST247). 
Mu50 is a clinical VISA strain isolated in 1997 from pus of a Japanese male child with a 
post-surgery infection who was unresponsive to vancomycin treatment (29). This isolate 
has a vancomycin MIC of 8 µg/mL (29), a thick cell wall relative to its sensitive parent 
strain (41), reduced autolytic rates (40), reduced cell-wall cross-linking (74), and an 
increased number of penta-peptide side chains (41). HIP6297 is also a clinical VISA 
strain that was isolated from the blood of a 79-year-old male patient who had renal 
disease and bacteremia at a hospital in New York, USA (36). It has a vancomycin MIC of 
8 µg/mL and a thick cell wall (36). LIM2, another clinical VISA strain was isolated from 
a 2-year old girl, in a hospital in France, who had an MRSA infection but was 
unresponsive to vancomycin treatment (75).  
Deletion of the msaABCR operon resulted in a significant decrease in vancomycin 
resistance in all three VISA strains as showed by their MICs. Specifically, the MIC of all 
three strains reduced from an intermediate resistance level of 6.25 µg/mL to a susceptible 




cloned in pCN34 plasmid into the deletion mutants, caused an increase in MIC to 3.125 
µg/mL confirming that the msaABCR operon was indeed responsible for the decrease in 
their MIC (Table 3.3). It is noteworthy here that, although the MIC of the complemented 
strains was not exactly in the wild type VISA range (4–8 µg/mL vancomycin), still it was 
higher than the sensitive range which is 2–4 µg/mL of vancomycin. A vancomycin 
sensitive strain N315, which is genetically related to strain Mu50 (76) was used as a 
control in this study. As expected, deletion of the msaABCR operon in N315 did not 
further reduce the vancomycin MIC. These results, taken together, show that the 
msaABCR operon is essential for vancomycin resistance in VISA strains of different 
genetic backgrounds.  
One of the hallmarks of VISA strains is the significant change in the growth rate 
relative to their sensitive counterparts (41). We measured the growth rates of the deletion 
mutants at different vancomycin concentrations (1, 2, and 3 µg/mL). We found that wild-
type strains displayed a steady growth rate and reached a stationary phase after 6 h at all 
three concentrations of vancomycin, whereas the three mutant strains did not show any 
growth after 6 h at a vancomycin concentration of 2 µg/mL or higher (Figure 3.2). 
Interestingly, all the mutants showed growth after a 20-h lag period unless the medium 
was replenished with vancomycin (Figure 3.3). This observation supports previous 
findings by Cui et al. 2000 (41), and confirms the increased susceptibility of the 




Figure 3.2. Growth curves of wild types Mu50, HIP6297 and LIM2 and their 
corresponding msaABCR deletion mutants in plain media and in different concentrations 




Figure 3.3. An elongated growth curve of wild type Mu50, HIP6297, and LIM2 and their 
respective msaABCR operon deletion mutants in medium containing 4 µg/ml vancomycin 
or medium replenished with 4 µg/ml vancomycin every 6 hours. 
To further characterize the population of the deletion mutants with regard to 
vancomycin resistance, we evaluated the homogeneity of the cells using a population 
analysis profile (Figure 3.4) (39). With wild-type strain Mu50, 10
10
 cells/mL were 
resistant to vancomycin at concentrations up to 3 µg/mL and 10
7
 cells/mL were resistant 
to a vancomycin concentration of 4 µg/mL. This indicated a small degree of 
heterogeneity in resistance. However, with the Mu50 msaABCR operon mutant, 10
9 
cells/mL were resistant to a vancomycin concentration of 1 µg/mL but no cells were 
resistant to a vancomycin concentration higher than 1 µg/mL. This indicated that the 
msaABCR operon mutant had a homogenously sensitive population structure with regard 
to vancomycin. Likewise, in the case of HIP6297, 10
10 
cells/mL were resistant to 4 
µg/mL of vancomycin and 10
9
 cells/mL were resistant to 5 µg/mL of vancomycin. The 
msaABCR operon mutant however possessed 10
9 
resistant cells per mL in the presence of 
3 µg/mL vancomycin and no resistant cells at higher concentrations. Wild type LIM2 
maintained 10
10
 cells/ml up to 5 µg/mL vancomycin, whereas its msaABCR mutant 
maintained 10
8




mutation of the msaABCR operon led to a population of cells that are homogenously 
sensitive to vancomycin. These results also suggested that the msaABCR operon is a 
regulator of resistance to vancomycin. Population analysis revealed that both of the 
mutants are homogenously sensitive to vancomycin. Indeed, the msaABCR deletion 
mutants did not show any resistant subpopulations in the presence of vancomycin at 
concentrations greater than 3 µg/mL. 
 
Figure 3.4. Population Analysis Profile of the wild types Mu50, HIP6297 and LIM2 and 
their corresponding msaABCR operon deletion mutants. 
This phenotype is of significance to the clinical treatment of VISA infections because 




to vancomycin. Indeed, Cui et al. 2003 (39) demonstrated that passage of strain Mu50 
through a drug-free medium (35 days) led to a drop in the vancomycin MIC from 8 
µg/mL to 2 µg/mL. However, population analysis of the passage-derived strain revealed a 
resistant subpopulation that was able to grow in the presence of up to 8 µg/mL of 
vancomycin (39). Such VISA strains have been defined as hetero-VISA (h-VISA) and 
present a treatment challenge. They are difficult to treat because of the rise of resistant 
subpopulations during treatment with vancomycin. For instance, the hetero-VISA strain 
Mu3, that is isogenic to Mu50, was isolated from a Japanese male patient who was 
unresponsive to vancomycin treatment. While Mu3 was initially characterized as 
susceptible to vancomycin (MIC = 2 µg/mL) according to CLSI criteria (77), when it was 
grown in the presence of a high concentration of vancomycin (2–9 µg/mL), it produced 
resistant subclones with a MIC of 6–8 µg/mL (comparable to Mu50) at a frequency of 1 
in 10
6
. This is relevant to patients infected with h-VISA strains, where peak tissue 
concentrations of vancomycin can be from 2 to 5 µg/mL depending on the dosage and 
frequency of treatment (78). These studies show that the rise of a resistant subpopulation 
is likely; however, the mechanism that leads to this is not yet understood. The absence of 
resistant subpopulations in the msaABCR operon deletion mutants is therefore very 
interesting and suggests a role of the operon in this process. Targeting regulators such as 
the msaABCR operon, which eliminate h-VISA, could therefore be potentially beneficial 
in developing new treatments for VISA infections. 
Previously, sarA and sigB inactivation in laboratory-derived vancomycin 
resistant/intermediate strains also resulted in a decrease in the vancomycin MIC. Singh et 








V20 had a vancomycin MIC of 4–6 µg/mL after population analysis compared 
with the wild-type strain, which had a vancomycin MIC of 12–14 µg/mL. The population 
analysis profile of the mutant strain displayed a homogenously sensitive population 
structure. Similarly, in the study by Lamichane-Khadka et al. 2009 (40), the sarA 
insertion mutant of BB270V15 showed an MIC of 3 µg/mL in agar dilution analysis while 
the wild type showed a vancomycin MIC of 8 µg/mL. In the population analysis profile, 
the mutant displayed a homogenously sensitive population structure. These findings 
support our hypothesis that mutation of major global regulators could have a profound 
effect on vancomycin resistance of VISA strains and may render the strains 
homogenously sensitive to vancomycin, which in turn could be clinically beneficial.   
The msaABCR operon regulates cell wall morphology 
Vancomycin is an inhibitor of cell wall synthesis in S. aureus and other Gram-
positive bacteria. It binds to the D-Ala-D-Ala residue of the pentapeptide sidechain of 
undecaprenylphosphate-MurNAc-pentapeptide, a cell wall precursor, and forms a stable 
non-covalent complex. As a result, this complex cannot be used in the biosynthesis of the 
cell wall (79). VISA strains, including Mu50 and HIP6297, have thick cell walls relative 
to their sensitive counterparts (36, 39, 41, 66, 80, 81). Cui et al. 2003 (39) showed that 
cell wall thickening is the most consistent feature of vancomycin intermediate and 
resistant strains. They also showed a positive correlation between the thickness of the cell 
wall and vancomycin MIC in a study of 48 S. aureus strains including VISA and VRSA 
strains. 
We examined cell wall thickness of the msaABCR operon mutants using 




cell wall thickness and a smoother texture relative to their wild-type strains (Table 3.4, 
Figure 3.5 a-b). These results suggest that the msaABCR operon plays a role in cell wall 
synthesis and contributes to cell wall thickness in VISA strains.  
Figure 3.5(a). Transmission Electron Micrograph of cell walls of wild type Mu50 (A), 
Mu50∆msaABCR (B), complemented mutants (C), and independent sample t-test of cell 





Figure 3.5(b). Transmission Electron Micrograph of cell walls of wild type HIP6297 (A), 
HIP6297∆msaABCR (B), complemented mutants (C), and independent sample t-test of 
cell wall thicknesses of all three strains (D). nm: nanometer, ***: p<0.0001 
The main location of cell wall synthesis in S. aureus has been shown to be the tip 
of the division septum of a bacterium and not the entire plasma membrane surface (17). 
Therefore, for vancomycin to prevent cell wall synthesis, it would have to diffuse through 
the cell wall to the tip of the division septum, which is approximately a 25-nm path (18). 
Pfeltz et al. (2000) proposed that a thickened cell wall increases the path that vancomycin 




the cell’s active site, which is the tip of the division septum in the cytoplasmic membrane 
(19, 20). This enables VISA and VRSA strains to continue synthesizing peptidoglycan 
and to survive in a vancomycin-containing environment. Our results suggest that the 
observed sensitivity of msaABCR operon mutants to vancomycin may be due to the 
decrease in cell wall thickness.  
As stated earlier, one of the key phenotypes of the msaABCR operon mutants is 
the prolonged lag phase in the vancomycin-containing medium, which may also be due to 
the thinning of the cell wall. A study comparing VSSA with VISA strains found that the 
length of the lag phase negatively correlated with cell wall thickness (39, 41). It was 
proposed that a thin cell wall binds vancomycin molecules at a significantly slower rate 
than in the wild-type strains and therefore removes drug molecules from the medium at a 
slower rate, which in turn results in a prolonged lag phase.  
Indeed, we observed a three-fold decrease in the binding of vancomycin 
molecules to the cell wall of the msaABCR mutants compared with the respective wild-
type cells (Figure 3.6). To date, however, the mechanistic link between the length of the 





Figure 3.6. Vancomycin binding assay with wild types Mu50, HIP6297, and LIM2 and 
their respective ∆msaABCR mutants, and complemented mutants. Vancomycin was added 
to a growing culture of cells. After 1 hour, cells were harvested and supernatant medium 
was dot blotted and detected with anti-vancomycin antibody. Figure shows that 
∆msaABCR mutants bind significantly less vancomycin than the wild types.   
The msaABCR operon regulates the expression of pbp4, sigB, and mprF in a strain-
dependent manner 
Studies with VISA strains have yielded descriptive assessments that correlate 
various phenotypes with vancomycin intermediate resistance. Collectively, these studies 
have resulted in a set of phenotypes that are commonly observed in VISA strains. Several 
studies have also used a variety of approaches to identify specific genes that are 
associated with vancomycin resistance. These include expression studies (e.g., 
microarray analysis) (47, 48, 73), and comparisons of isogenic resistant and sensitive 
strains by targeted mutagenesis experiments (24, 45, 53, 59, 72, 82, 83). Collectively, 
these studies have identified the following regulator genes as critical to intermediate 
vancomycin resistance in S. aureus: pbp4, sigB, walKR, graS, graR, mprF, dltA, vraS, 




We examined the expression of these genes in the msaABCR operon mutants 
using quantitative RT-PCR in the absence and presence of vancomycin. No significant 
change in gene expression was observed for graR, graS, dltA, vraSR, and walkR in either 
of the strains. However, we found that expression of pbp4 was increased and that of sigB 
was decreased in the Mu50 msaABCR mutant and expression of mprF was decreased in 
the HIP6297 msaABCR mutant (Figure 3.8 a-b). 
The msaABCR mutant of Mu50, but not HIP6297, showed a three-fold increase in 
pbp4 expression both in the presence and absence of vancomycin (Figure 3.8 a). We 
confirmed the increase in the expression of PBP4 in the Mu50 msaABCR operon mutant 
by performing a fluorescent penicillin-binding assay with Bocillin-FL to measure the 
levels of PBP4 protein. We found that the Mu50 msaABCR operon mutant produces 
6.003-fold higher levels of PBP4 compared with the wild type (Figure 3.7).  
 
Figure 3.7. Fluorescent penicillin binding assay from purified cell membranes of wild 
type Mu50, Mu50∆msaABCR mutant, and complemented mutants. Lower panel shows 




 PBP4 is involved in cell wall biosynthesis as a DD-carboxypeptidase enzyme 
(84). PBP4 is required for cleavage of the peptide bond of D-Ala-D-Ala residue of the 
pentapeptide sidechain of undecaprenylphosphate-MurNAc-pentapeptide prior to cross-
linking between the penultimate alanine and the third lysine of another NAM. Because 
vancomycin binds to D-Ala-D-Ala residues, any vancomycin-bound residue becomes 
unavailable for PBP4 and therefore cannot be used for crosslinking. VISA strains 
produce significantly less PBP4 compared with the VSSA strains (42, 85). Deletion of 
pbp4 in the VSSA strain N315 caused an increase in the vancomycin MIC, which was 
restored by complementing pbp4, suggesting that the function of pbp4 is directly related 
to the vancomycin MIC (42). Although the genetic regulation of pbp4 in VISA strains is 
not yet understood, it has been proposed that reduced expression of PBP4 in VISA strains 
results in an increase of intact D-Ala-D-Ala and consequently a build-up of uncrosslinked 
muropeptide monomers in the cell wall. These monomers hinder the diffusion of 
vancomycin molecules by attaching the drug molecules to the intact D-Ala-D-Ala 
termini. The attached vancomycin molecules are thought to become part of the resistance 
mechanism by sterically hindering additional vancomycin molecules during the diffusion 
process (86). These findings indicate that there is a negative correlation between the 
expression level of pbp4 and resistance to vancomycin. Hence, our results suggest that 
the msaABCR operon negatively controls the expression of pbp4 in Mu50 and the 
increased sensitivity of the Mu50 msaABCR mutant to vancomycin may be attributed to 
the increased PBP4 activity. Further studies are needed to define the relationship between 




Gram-positive bacteria respond to stress by expressing alternative sigma factors 
such as sigma B (encoded by sigB). The presence of antibiotics, such as methicillin or 
vancomycin, has been shown to activate the expression of sigma B in S. aureus, 
implicating this factor in antibiotic resistance (72, 87, 88). 
Expression of sigB was significantly reduced in the msaABCR mutant of the 
Mu50 strain compared with the wild type in both the absence (4.91-fold) and presence of 
vancomycin (7.15-fold). Expression of asp23, which is directly under the regulation of 
sigB, was also down-regulated in Mu50. Interestingly, this change in expression was not 
observed in strain HIP6297, indicating that this regulatory effect is strain dependent. 
Mutation of sigB has been shown to reduce vancomycin resistance in a passage-derived 
resistant strain of S. aureus (72). Conversely, activation or overexpression of sigB led to 
thickening of the cell wall and increased vancomycin resistance in VSSA strain N315 
(46, 49). Cell wall inhibitor antibiotics induce a stress response in S. aureus cells (63). 
Resistant cells may have the capacity to respond to and counteract the stress more 
efficiently than their sensitive counterparts. We propose that the msaABCR operon 
mutant of Mu50, with decreased sigB expression, becomes more susceptible to stress 
conditions including the presence of vancomycin in the medium. However, the 
mechanism by which the msaABCR operon regulates sigB and the reason why this 
regulation occurs in strain Mu50, but not in strain HIP6297, is currently unclear.  
Another regulator, which is directly under the control of the stress response 
system, mprF, was found to be significantly down-regulated in the msaABCR operon 
deletion mutant of HIP6297 but not of Mu50. MprF is a putative trans-membrane protein 




phospholipid that contributes to a net positive charge on the cell surface. MprF-deficient 
mutants have been shown to be sensitized to cationic antimicrobial peptides of the 
immune system (89, 90) and vancomycin (45). This phenotype was attributed to the fact 
that because MprF mediates the synthesis of a positively charged lipid, absence of it leads 
to the accumulation of a net negative charge on the cell surface, which attracts cationic or 
positively charged molecules including vancomycin. Ruzin et al. 2003 (45) showed that 
an mprF mutant indeed binds more vancomycin to the membrane than its corresponding 
wild type. This may be contributing to the increased susceptibility of the HIP6297 
msaABCR operon deletion mutant to vancomycin.  
The strain-dependent variations among VISA isolates, both in terms of phenotype 
and genetic mutations, are not uncommon. Reduced vancomycin sensitivity has been 
reported to be unstable for some isolates such as HIP5836 and Mu50 (91) but not in the 





V20 (19). Cell wall thickening has been shown in most VISA isolates but to 
varying degrees. For instance, the thickness of the cell wall in strains JH9 and JH14 (20) 
appears to be many fold higher than that observed in strain Mu50. Reduced crosslinking 
of the muropeptides appears to be correlated with the vancomycin MIC in many VISA 
strains but not all (30). Boyle-Vavra et al. 2001 (30) demonstrated that a vancomycin 
trapping hypothesis and a uniform cascade of genetic events might not explain the 
resistance phenotype in every VISA strain isolated. However in this study, a 
reorganization of the cell wall was found to be common among all VISA isolates. Non-
amidated residues of glutamic acids have been shown to play a role in the resistance 




correlated with vancomycin resistance either in terms of altered expression or point 
mutations, but none of these have been found to be present without exception. When 
analyzing the results of multiple studies (24, 42, 47, 86), it appears that, although 
theoretically lowered expression of PBP4 could be correlated with a higher vancomycin 
MIC, the laboratory-derived VISA mutants do not follow this pattern.   
Strain-dependent variations are also found in terms of mutations in response 
regulator genes. Although mutations in genes such as vraSR, graSR, clpP, and walKR 
have been correlated with a VISA phenotype, sequence analysis of these genes in 39 
VISA isolates revealed that none of these mutations are universal among all VISA strains 
(24). While 27 VISA strains possessed mutations in walK, only a few of these mutations 
were at the same site in the gene. Similarly, three isolates harbored mutations in clpP, 
four isolates had mutations in graR, and eight isolates had vraS mutations, but all of these 
mutations were at different sites within the genes. Shoji et al. (2011) proposed that these 
differences indicate the existence of alternative pathways in different VISA isolates for 
the establishment of vancomycin resistance (24).  
Strain-dependent variation has also been observed in the function of global 
regulators in S. aureus. Zielinska et al. (2011) studied the regulatory role of sarA on the 
alpha-toxin phenotype of laboratory and clinical strains of S. aureus, and observed that 
sarA exerts a strain-dependent effect on the transcription of RNAIII and hla (92). Blevins 
et al. (2002) also demonstrated a strain-dependent regulatory role for sarA and agr (93). 
In this context, variations between strains Mu50 and HIP6297 would be expected. For 
instance, Mu50 harbors one mutation in VraS (I5N) and one in GraR (N197S), HIP6297 




Mu50 and HIP6297 strains have been described to have inactivated PBP4 (86), our 
results indicate that the msaABCR operon exerts a strain-dependent effect on pbp4 
expression.  
Strain variations in VISA isolates, such as the ones in this study, have made it 
difficult to define a common mechanism to the establishment of the VISA phenotype. In 
conclusion, we have shown that the msaABCR operon plays a key role in intermediate 
vancomycin resistance and that its inactivation leads to homogeneous vancomycin 
sensitivity despite strain differences.  
Figure 3.8(a). Transcription profile of genes linked to vancomycin resistance in 




Figure 3.8(b). Transcription profile of genes linked to vancomycin resistance in 





Strains and Plasmids used in this study 
Strains or Plasmids Relevant feature Reference or 
Source 
Strains  
E. coli  
TOP10 F
−
ϕ80lacZ∆M15 recA1 Life 
Technologies 
S. aureus   




, ST5 NARSA 
Mu50∆msaABCR msaABCR operon knock out This study 
Mu50 comp. Mu50∆msaABCR (pCN34-msaABCR operon) This study 
HIP6297 VISA, mecA
+
, ST5 NARSA 
HIP6297∆msaABCR msaABCR operon knock out This study 





, ST247 BEI Resources 
LIM2∆msaABCR msaABCR operon knock out This study 
LIM2 comp. LIM2∆msaABCR (pCN34-msaABCR operon) This study 
   





 ; Shuttle vector, temperature 
sensitive 
Bae et al., 
2006 
pKOR1- ∆msaABCR Upstream and downstream fragment of 
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) - msaABCR 
operon 
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Table 3.2  
Primers used in this study 
Primers Sequences (5’  3’) 
 




Operon del 2 ATGACTGGATCCTATTAAAGACCCCTTCCATACTTCAAAAAC 
Operon del 3 ATGACTGGATCCTTTCATGATGCTTGTTTAAAGTGTGGTAT 













gyrB RT F CAACTATGAAACATTACAGCAGCGT 
gyrB RT R TGTGGCATATCCTGAGTTATATTGAAT 
mprF RT F GAACCACCGTTTTCAACTGAA 
mprF RT R GTAAATCTAACTCTGGCAACCATC 
dltA RT F ATGTTTAGCATCAGGCGGTAC 
dltA RT R ACTTGGGAAACGGCTCACTAA 
rnaIII RT F CTGAGTCCAAGGAAACTAACTCTAC 
rnaIII RT R TGATTTCAATGGCACAAGAT 
graR RT F GTTGCTGGTATTGAAGATTTCG 
graR RT R CGCCAAGTTCCATACTCATCAC 
graS RT F CACCTGTGACAGCCATGAAATTA 
graS RT R CATCAATGACCATGCGTTTAAGTGACA 
walKR RT F AAACAACTACAATCCCTTCATACTAA 
walKR RT R CTTGACGGTTGGCATACTCACTTAA 
pbp4 RT F CCGTTGGATTGACGAAATGT 
pbp4 RT R ACCAGCGATTTCGTTGATTT 
gyrA RT F CATTGCCAGATGTTCGTGAC 
gyrA RT R CCGGTGTCATACCTTGTTCA 
sigB RT F AACCGATACGCTCACCTGTC 









Vancomycin MIC of Wild types, msaABCR operon deletion mutants, and complemented 
mutants 
 
Strains   Vancomycin MIC (µg/ml) 
 











∆msaABCR 1.56 1.56 1.56 1.56 
Complemented mutant (pCN34-msaABCR) 3.13 3.13 3.13 1.56 
 
Table 3.4 
Cell wall thicknesses of wild types, msaABCR operon deletion mutants, and 
complemented mutants 
 
Strains Mean thickness of cell wall (nm ± SE) 
 






50.83 ± 3.82 
 
24.23 ± .91 
 
44.5 ± 3.98 
HIP6297 
 
41.8 ± 2.65 25.6 ± 1.61 51.4 ± 2.63 
 







MOLECULAR AND PHENOTYPIC CHARACTERIZATION OF METHICILLIN-
RESISTANT Staphylococcus aureus ISOLATES CAUSING BACTEREMIA AT A 
MAJOR HOSPITAL IN SOUTHERN MISSISSIPPI 
Abstract 
Staphylococcus aureus is the predominant cause of bacteremia worldwide. 
Distribution of methicillin-resistant Staphylococcus aureus (MRSA) tends to be 
geographically unique. We assessed molecular epidemiology and antibiotic resistance of 
MRSA isolates causing bacteremia in Southern Mississippi.  
We collected 30 MRSA blood isolates over 1 year, which were subjected to 
staphylococcal chromosomal cassette mec (SCCmec) typing, pulsed field gel 
electrophoresis (PFGE), multilocus sequence typing (MLST), and antibiotic resistance 
profiling. Risk factors underlying bacteremia were analyzed by Fisher’s exact test and 
regression analysis.  
All MRSA isolates were mecA positive and 70% were SCCmec type IV, 
indicating community-acquired infections, and 30% were SCCmec type II, of which 50% 
were Panton–Valentine leukocidin (PVL) negative, indicating hospital-acquired 
infections. Most isolates (97%) were resistant to oxacillin and erythromycin and 30% to 
clindamycin. Risk factor analysis revealed a strong association of prior hospitalization, 
prior antibiotic usage, nursing home origin, and presence of PVL with MRSA isolates 




Diverse genetic backgrounds in terms of SCCmec, PFGE, and MLST types of 
MRSA were identified as causing bacteremia in Mississippi. A strong association of PVL 
with high vancomycin MIC is one of the important findings of our study. 
Introduction 
Staphylococcus aureus is a major human pathogen responsible for both 
community and hospital-associated infections. It is the causative agent of a wide array of 
diseases from skin and soft tissue infections (SSTIs) to more life-threatening conditions 
such as endocarditis, osteomyelitis, and septic arthritis. Methicillin-resistant 
Staphylococcus aureus (MRSA) strains are causing increasingly complex public health 
problems in both community and hospital settings. Initially, MRSA strains were largely 
confined to hospitals and were referred to as hospital-acquired MRSA (HA-MRSA), 
causing treatment difficulties, especially in patients with prior exposure to antibiotics. 
During the past two decades, S. aureus infections have been worsened by the emergence 
of community-acquired MRSA (CA-MRSA) (94). The United States has an epidemic 
caused by CA-MRSA isolates (95-97). CA-MRSA isolates are clinically significant 
because they can also cause severe disease in individuals who are apparently healthy and 
without any predisposing risk factors (94, 97).  
CA-MRSA isolates can be distinguished from HA-MRSA by molecular typing 
tools. Although all the MRSA isolates carry staphylococcal chromosomal cassette mec 
(SCCmec), the length of the SCCmec elements varies between CA- and HA-MRSA 
isolates. HA-MRSA isolates typically carry SCCmec types I, II or III, which are longer in 




MRSA isolates do not typically carry Panton–Valentine leukocidin (PVL) genes (lukS-PV 
and lukF-PV), whereas community-acquired isolates frequently carry PVL (94).  
Bacteremia caused by MRSA isolates is associated with a higher risk of mortality 
compared with methicillin-susceptible Staphylococcus aureus (MSSA) (98). Given the 
importance of invasive MRSA infections in both community and healthcare settings, it is 
imperative to understand the clonal variation among clinical isolates. Isolates belonging 
to a certain clonal background have been shown to be more prevalent and virulent than 
others (99). In the United States, pulsed field type USA300 has been the dominant strain 
causing MRSA infections in community settings. Although studies by The Center for 
Disease Control and Prevention (CDC) indicated that USA100 used to be the 
predominant type causing clinical bacteremia, others reported that USA300 is becoming 
more dominant even in hospital settings (100). Tenover et al. (100) studied the 
prevalence of USA100 and USA300 isolates in nine geographical zones in the United 
States. The results showed that USA100 is predominant in mountain (60%), west north 
central (45%), east north central (50%) and New England (70%) regions. In contrast, 
USA300 was found to be predominant in the Pacific (49%), west south central (79%), 
South Atlantic (42%) and Mid-Atlantic (53%) regions. However, notably, there were no 
data reported from the Southeast United States (Mississippi, Alabama, Tennessee and 
Kentucky). As a result of this gap in the epidemiological data of MRSA isolates in this 
area, we carried out the first ever molecular and phenotypic characterization of MRSA 
isolates causing bacteremia in Southern Mississippi. A retrospective cohort study carried 
out between October 1995 and December 2003 showed that patients with MRSA 




their infection (P < 0.01), and consequently a higher mortality rate (101). Clearly, MRSA 
infection in blood indicates a more robust disease state. Therefore, it is important to study 
blood isolates to understand the degree of virulence of the MRSA isolates causing the 
epidemic.  
The fact that relatively few antibiotics are available to treat MRSA infections has 
made the treatment more expensive and difficult. For many years vancomycin has been 
the drug of choice for MRSA infections. However, since the late 1990s, the situation has 
been exacerbated by the emergence of vancomycin intermediate-resistant and resistant S. 
aureus strains. Continued use of vancomycin has been shown to accelerate the 
appearance of resistant sub-clones both in the laboratory (77) and in hospital settings (29, 
36, 75). Hence, for effective treatment with vancomycin, early detection of underlying 
risk factors that may be associated with the increased vancomycin resistance is important. 
In this study, we isolated and collected 30 bacteremia-causing MRSA isolates, analyzed 
their clonality by molecular methods, and assessed their antibiotic resistance profile. We 
also analyzed the association of predisposing risk factors with the outcome of increased 
vancomycin resistance in certain strains. 
Materials and Methods 
Research ethics 
The study was approved by the Institutional Review Board of the University of 
Southern Mississippi and the Forrest General Hospital. Based on the protocol used, a 






Collection and maintenance of isolates 
Clinical isolates of MRSA strains from patients were collected from the 
microbiology laboratory of a large referral level II trauma hospital in Forrest County in 
Southern Mississippi. Isolates were collected between March 2013 and February 2014. 
Once an MRSA organism was isolated from a positive blood culture, two or three 
colonies were suspended into the Prompt Inoculation System-D (Siemens Medical 
Solutions, Malvern, PA, USA). This is a microdilution procedure for susceptibility 
testing that helps to determine the standardized inoculum needed for MicroScan. The 
suspension was inoculated onto the MicroScan Gram Positive panel (Siemens Medical 
Solutions) and loaded onto the MicroScan instrument for incubation, followed by 
addition of reagents, and reading of the panel. The following day, the panel was 
processed and observed by an experienced technologist to confirm the result and purity of 
the culture. Once the isolates were confirmed as MRSA, they were re-streaked and 
maintained in DMSO stocks at –80°C. A database of information about the source of 
infections was maintained using de-identifiers.  
Identification of virulence factors: mecA, PVL and hlg 
The presence of mecA, PVL and hlg in the MRSA isolates was tested using 
polymerase chain reaction (PCR). Chromosomal DNA of the isolates was amplified with 
the primers listed in Table 4.1. The presence of a band in agarose gel from the respective 
PCR compared with a positive control indicates the presence of the gene. 
Pulsed field gel electrophoresis (PFGE) 
PFGE was performed as described previously (102). SmaI-digested chromosomal 




dendrogram was generated in Bionumerics (version 5.0.1, Applied Maths, Austin, TX, 
USA) using 80% similarity cutoff. Banding patterns were compared with standard 
banding patterns of known PFGE types of S. aureus determined by McDougal et al. 
(102).  
Multilocus sequence typing (MLST) 
MLST of the MRSA isolates was performed as described previously (103). Seven 
housekeeping genes were amplified and sequenced using the primers listed in Table 4.1. 
Sequence data for each gene were individually analyzed to determine the sequence type 
for isolates according to the criteria provided for S. aureus using the web-based tool 
MLST (http://www.mlst.net). 
SCCmec typing 
SCCmec typing was performed as described by Ghaznavi-Rad et al. (104). A 
multiplex PCR was performed using the chromosomal DNA of the isolates as a template 
and a primer mastermix containing all the primers at a final concentration of 100 nM, 
using a Qiagen Multiplex PCR kit (Qiagen, Valencia, CA, USA). The primers used for 
SCCmec typing are listed in Table 4.1. The PCR product was run in 2.0% agarose gel. 
SCCmec type of the isolates was determined by comparing the band pattern of the PCR 
product with the standard pattern as described previously (104). 
Antibiotic susceptibility testing 
Antibiotic susceptibility of all isolates was tested in triplicate using the broth 
microdilution method according to the Clinical and Laboratory Standards Institute 
guidelines (64). Mueller–Hinton broth supplemented with 2% NaCl was used for all 






CFU/ml bacteria (65). After overnight incubation at 35°C, wells were analyzed for 
visible bacterial growth as exhibited by turbidity. The lowest concentration of antibiotic 
that prevented bacterial growth was considered to be the minimum inhibitory 
concentration (MIC). The antibiotics used in this study were vancomycin, oxacillin, 
erythromycin, clindamycin, rifampin, amoxicillin/clavulanic acid (Augmentin), 
trimethoprim/sulfamethoxazole (Bactrim), and linezolid. Isolates were considered 
resistant or sensitive based on the antibiotic breakpoints given on DAILYMED 
(dailymed.nlm.nih.gov). 
Risk factor analysis  
The medical records of all selected blood cultures positive for MRSA were 
reviewed for the following variables: demographics (age, sex, race, and body mass 
index); comorbidity (diabetes mellitus, chronic skin condition, chronic kidney disease, 
chronic heart failure, obesity, immunosuppression, and HIV infection); invasive 
procedures (surgery, dialysis, intravenous catheterization, and mechanical ventilation); 
history (smoking, drug usage, prior hospitalization, and antibiotic usage); and source of 
bacteremia. 
Data analysis and statistical tests 
For analysis of the collected data, SCCmec, PFGE and MLST types were 
combined for each isolate. From the antimicrobial resistance data, the resistance pattern 
of each isolate was determined. The combined molecular types were then cross-tabulated 
with antimicrobial resistance patterns. Associations between molecular types and 
resistance pattern, between MLST and PFGE types, and between SCCmec and PFGE 




significant. All statistical analyses were performed using SPSS version 20. Risk factors 
were binary coded in SPSS. To measure the association between risk factors and 
vancomycin MIC >1 µg/ml, a crude analysis was first performed by Fisher’s exact test. 
This test was chosen over χ
2
 because of the small sample size. The factors that displayed 
a P value < 0.2 were used to perform binary logistic regression to determine the odds 
ratio (OR).  
Results 
Overview 
During the period between March 2013 and February 2014, a total of 322 clinical 
MRSA isolates were collected from a regional hospital in Southern Mississippi. Thirty 
blood isolates were selected for this study. Among all the blood cultures in the hospital, 
the incidence of MRSA infection was estimated to be 49 for every 10 000 patients. The 
proportion of blood MRSA isolates was estimated to be 7.1% of all MRSA isolates.  
Clinical and epidemiological data  
The majority of patients (72%) had a history of previous antibiotic usage. 
Regarding the source of infection, pneumonia was found to be the most common source 
of bacteremia (28.5%), followed by osteomyelitis (17.8%), and dialysis catheter infection 
(10.7%). Diabetes mellitus was found to be the most common comorbidity among the 
patients (51.7%). Details of the demographic data are listed in Table 4.2.    
Pulsed field types and multilocus sequence types  
PFGE has been a valuable tool for investigating S. aureus outbreaks, especially in 
hospitals because of its high resolving power (105-111). McDougal et al. (102) described 




identified eight distinct lineages (USA100–800) that incorporate both oxacillin-resistant 
and -sensitive strains. Since then, USA types have been used to describe the 
epidemiological spread of pathogenic S. aureus strains worldwide.   
In the present study, using an 80% similarity cutoff, blood isolates of MRSA 
belonged to two major clusters designated A and B (Figure 4.1). Cluster A was composed 
of isolates with USA100 and USA800 types, whereas Cluster B was composed of 
USA300 and USA700 type isolates. One isolate (USMFG160) was novel; however, it 
appeared closest to USA800 isolates in the PFGE typing. Overall, USA300 was found to 
be the most common pulsed field type (40%) among the bacteremia-causing MRSA 
isolates. USA100, 700 and 800 accounted for 23.3, 20 and 13.3% of the isolates, 





Figure 4.1. PFGE pattern and phylogenetic tree of the MRSA isolates 
MLST is based on sequence analysis of seven housekeeping genes (arcC, aroE, 
glpF, gmk, pta, tpi and yqiL) of S. aureus. It gives an indication of clonal evolution of 
MRSA. Different sequences of these genes are assigned unique allele numbers. 
Combination of all seven genes resulted in an allelic profile or sequence type. In the 
present study, blood isolates of MRSA belonged to five distinct sequence types. Among 
these, ST5 accounted for 40% of the isolates, constituting the largest group. ST8, ST72 
and ST100 were found in 37, 20 and 3% of the isolates, respectively (Figure 4.2 B). One 
isolate (USMFG95) was novel. McDougal et al. (102) have observed a strong association 




type could be assigned a unique MLST type such as USA100 and USA800 sharing ST5, 
and USA300 and USA700 isolates were ST8 and ST72, respectively. Our results largely 
reflected these findings. For example, all USA100 and USA800 isolates were found to be 
ST5. All but one USA300 isolates were found to be ST8, and only one (USMFG100) was 
determined to be ST100. All but one USA700 isolates were found to be ST72. There was 
a strong association between MLST and PFGE types (P < 0.001) of the blood isolates of 
MRSA. 
SCCmec types of bacteremia isolates 
The methicillin resistance of S. aureus is caused by the presence of the mecA gene 
that encodes a 78-kDa penicillin-binding protein (PBP2a or PBP2′). Compared to other 
PBPs, PBP2a has a lower affinity for β-lactam antibiotics. As a result, even in the 
presence of these antibiotics, the peptidoglycan layer is not disrupted and the bacterium 
survives (11, 12). The mecA gene is housed within the mec operon together with its 
regulatory genes mecI and mecR1 (11). Since the first detection of the SCCmec element 
from N315 in 1999, multiple mec types have been identified because of the 
hypervariability of SCCmec elements. Nine SCCmec types (I–VIII and VT) have been 
detected to date. These are distinguished by the ccr gene complex, which helps in 
excision and insertion of SCCmec elements (13-15). Clones of unique SCCmec types 
have driven the epidemic of MRSA worldwide. For instance, SCCmec type I was first 
discovered in the United Kingdom in 1961 and spread around the world during the 1960s. 
Following that in 1982, SCCmec type II was discovered in Japan and this clone also 




Therefore, in addition to MLST and PFGE, SCCmec typing can reveal information 
pertinent for epidemiological analysis of MRSA strains (12). 
In our analysis, all blood isolates were found to possess the mecA gene (Table 
4.3), and 67% of the isolates were found to carry SCCmec type IV by multiplex PCR 
(Figure 4.2 C). All but one USA300 strains were mec type IV. This isolate was found to 
be mec type II. All the USA700 and USA800 isolates also possessed mec type IV. 
USA100 isolates were found exclusively to possess mec type II, which accounted for 
29% of the blood isolates. Only one isolate, USMFG160, which was identified as novel 
by PFGE, was found to possess mec type V (3%). A strong association was found 
between the PFGE and SCCmec types of the blood isolates of MRSA (P < 0.001).  
Frequency of PVL and hlg in bacteremia isolates 
PVL is capable of lysing the cell membrane of human neutrophils. Although its 
role in pathogenesis is controversial, PVL has been strongly associated with several CA-
MRSA infections (112-115). Naimi et al. (10) showed with a large number of MRSA 
cases that while 77% of CA-MRSA possessed the PVL gene, only 6% of HA-MRSA 
were positive for PVL. Despite its strong correlation with CA-MRSA, it is not clear 
whether PVL contribute to the fitness or virulence of the CA-MRSA strains (94). HA-
MRSA strains are typically characterized by SCCmec type II and an absence of PVL. 
Therefore, despite the controversy about its function, the presence or absence of PVL 
genes may be important to determine if a particular isolate is community or hospital 
acquired. Hemolysin gamma (γ) (hlg) gene is another virulence factor, which has a 




In our study, all USA300 strains were PVL positive (Table 4.3). USA100 strains 
(SCCmec type II) were mostly found to be PVL negative, except for two isolates 
(USMFG23 and 24). It is likely that USA100, SCCmec II, and PVL-negative strains are 
HA-MRSA (17% of all isolates). About 50% of all USA700 and USA800 isolates were 
found to be PVL positive, while the rest were PVL negative. All isolates were found to be 
hlg positive (Table 4.3). 
Antibiotic susceptibility analysis 
All isolates in this study were found to be resistant to oxacillin and 
amoxicillin/clavulanic acid. The majority of the isolates (93%) were resistant to 
erythromycin followed by 30% resistant to clindamycin. All isolates were found to be 
sensitive to vancomycin, rifampin, trimethoprim/sulfamethoxazole, and linezolid. 
Although we did not find any vancomycin intermediate or resistant strains, we noted that 
some isolates had higher MIC for vancomycin than others. Specifically, while 13 isolates 
had MIC of 0.5 µg/mL, seven had MIC of 1 µg/mL, and 10 had MIC >1 µg/ml for 
vancomycin (Table 4.4). Our antibiotic susceptibility analysis of blood isolates reflected 
the susceptibility record maintained by the hospital in the period between January and 
June 2013, which revealed that all MRSA isolates tested were resistant to oxacillin and 
amoxicillin/clavulanic acid. Ninety-one percent were resistant to erythromycin, 30% to 
clindamycin, and 1% to trimethoprim/sulfamethoxazole. All MRSA isolates were 
sensitive to vancomycin and linezolid. There was no significant association between 
antibiotic resistance patterns and combined molecular types (PFGE/MLST/SCCmec) of 
strains (P = 0.140). In other words, antibiotic resistance patterns were distributed across 





Figure 4.2. A. Distribution of PFGE types among the isolates causing bacteremia in 
Southern Mississippi; B. Distribution of MLST types among bacteremia-causing isolates; 
C. Distribution of SCCmec types in bacteremia-causing MRSA isolates; D. Distribution 








Vancomycin is the most frequently used drug in treating bacteremia caused by 
MRSA. Most of the patients who developed bacteremia had a history of antibiotic usage 
(Table 4.5). Moreover, as mentioned earlier, we found 10 isolates (33%) with MIC >1 
µg/ml for vancomycin from our susceptibility analysis (Table 4.4). Among these, five 
isolates showed MIC of 2 µg/ml. Repeated use of vancomycin gives rise to resistant sub-
clones with increased MIC compared with that of susceptible strains, and results in more 
complicated, life-threatening conditions (77). We aimed to identify any predisposing risk 
factors associated with this phenomenon. A detailed review of the medical records of the 
patients and statistical univariate analysis (crude analysis) revealed that several risk 
factors were associated with MIC >1 µg/ml for vancomycin. Table 4.5 lists all the risk 
factors analyzed in this study. The factors with P < 0.2 in the univariate analysis were 
further analyzed by logistic regression to determine OR. The presence of the PVL gene 
was strongly associated with vancomycin MIC >1 µg/mL (P = 0.01) and showed a high 
OR in regression analysis. With the exception of smoking, all the other factors revealed 
an OR >1. This suggests that the odds of having an MRSA isolate with vancomycin MIC 
>1 µg/ml will increase in patients with prior usage of antibiotics, prior hospitalization, 
coming from a nursing home, and being infected by a strain possessing PVL. 
Discussion 
To the best of our knowledge, this is the first study to assess systematically the 
clinical and molecular epidemiology of bacteremia by MRSA isolates in Mississippi. The 
hospital where the isolates were collected is a referral healthcare facility in Southern 




MRSA have been performed in Mississippi. A CDC study at a prison in Mississippi 
revealed MRSA infections among 4.9% of the inmates. Among 59 cases tested, 41 were 
confirmed MRSA by CDC (116). However, limited molecular analysis was done. 
Our analysis showed that the majority of bacteremia cases were caused by 
USA300-ST8-SCCmec IV isolates. This predominance of USA300 was observed in 
studies done in other regions of the United States as well. Tenover et al. (100) analyzed 
493 isolates from 23 US laboratories by PFGE typing. They found that USA300 was 
predominant in the Pacific, west south central, South Atlantic and mid-Atlantic regions, 
whereas in the mountain, west north central and east north central regions, USA100 was 
predominant. However, the authors noted that the percentage of USA300 in the blood 
isolates increased significantly compared with a previous study performed by CDC- 
Active Bacterial Core surveillance (ABCs) in 2005–2006 with 1984 blood isolates. The 
predominance of CA-MRSA over HA-MRSA in the hospital setting has been 
mathematically modeled by D’Agata et al. (117). They predicted that CA-MRSA would 
eventually become dominant in hospitals. An increasing community reservoir of CA-
MRSA strains results in a greater influx of CA-MRSA-infected patients into hospitals, 
which contributes greatly to the dominance of CA-MRSA over HA-MRSA. Moreover, 
CA-MRSA isolates carry smaller SCCmec genes, do not carry antibiotic resistance genes 
unlike HA-MRSA strains, and grow more rapidly than HA-MRSA, which combined 
gives CA-MRSA strains a competitive advantage and increased chance of colonizing, to 
eventually outcompete HA-MRSA. Our observation from the hospitalized patients 
confirms the predominance of USA300 isolates (CA-MRSA) in bacteremia-causing 




Although USA300 comprised the major portion of the isolates, regarding 
antibiotic resistance, USA100-ST5-SCCmec II isolates were more resistant against 
multiple drugs. Many of these isolates were PVL negative. USA300 isolates are typically 
susceptible to fluoroquinolones and clindamycin (102). However, in this study, we found 
that 30% of USA300 isolates were clindamycin resistant. This supports previous 
observations in other studies that reported emerging resistance of USA300 isolates 
against clindamycin (95, 118-120).  
An important finding of our study was the strong association of the PVL genes 
(lukS-PV and lukF-PV) with elevated MIC for vancomycin. In the univariate analysis of 
association of risk factors, we found that prior antibiotic use (P = 0.03) and presence of 
PVL (P = 0.01) had a strong association with vancomycin MIC >1 µg/ml. A high OR 
(>1) in the regression analysis indicates that prior antibiotic use by a patient or presence 
of PVL genes in an isolate increases the chance of vancomycin MIC >1 µg/ml. Prior 
antibiotic use is known to be a leading cause of the emergence of vancomycin resistance 
in a hospital setting (29, 36, 75). However, the contribution of PVL genes in the resistant 
isolates is unclear. PVL is a leukocidin that is capable of killing human neutrophils by 
lysing their cell membranes. Although it is regarded as a virulence factor for CA-MRSA 
isolates, contradictory findings have been reported (112-115, 121). Voyich et al. (112) 
and Wardenburg et al. (113) showed that the presence or absence of PVL did not affect 
the capacity of a strain for sepsis formation or mortality rate in a mouse model. In 
contrast, Labandeira-Ray et al. (114) showed overexpression of PVL caused necrotizing 
pneumonia in a mouse model, suggesting that PVL contributes significantly to the 




strains might possess a survival benefit in the early hours of infection over the PVL-
negative mutants. Hongo et al. (121) showed that although PVL did not lyse mouse 
neutrophils, anti-PVL antibodies were able to reduce the lysing activity of USA300 and 
USA400 strains against human neutrophils, suggesting that PVL may be important for 
CA-MRSA infection in humans, and that mice may not be suitable model for this study. 
David et al. (94) pointed towards a variation in the amino acid sequence of PVL genes in 
the MRSA strains to be the possible reason for these contradictory results. However, any 
relation between the presence of PVL genes and vancomycin MIC has not been studied, 
and further research is needed. Although it is unclear why PVL is strongly associated 
with elevated vancomycin MIC, it may have been due to our relatively small sample size 
of MRSA-infected patients, which may have resulted in skewed observation. Another 
limitation of this study was that the isolates were collected from a group of ill individuals, 
and less severely infected cases may have other risk factors that were not discovered in 
this study. 
In conclusion, to the best of our knowledge, this is the first report of systematic 
molecular epidemiological analysis of MRSA isolates in Mississippi. Collectively our 
data show the presence of both CA-MRSA and HA-MRSA isolates among bacteremia-
causing MRSA in this region. The prevalence of USA300 isolates in a hospital setting is 
an extension of a nationwide observation and mathematical prediction; however, the 










 Primers used in this study 
Experiment Primer name Sequence (5’ to 3’) Reference 
SCCmec typing Type I F GCTTTAAAGAGTGTCGTTACAGG Ghaznavi-Rad et al.(104)  
Type I R GTTCTCTCATAGTATGACGTCC 
Type II F GATTACTTCAGAACCAGGTCAT 
Type II R TAAACTGTGTCACACGATCCAT 
Type III F CATTTGTGAAACACAGTACG 
Type III R GTTATTGAGACTCCTAAAGC 
Type IVa F GCCTTATTCGAAGAAACCG 
Type IVa R CTACTCTTCTGAAAAGCGTCG 
Type IVb F AGTACATTTTATCTTTGCGTA 
Type IVb R AGTCATCTTCAATATGGAGAAAGTA 
Type IVc F TCTATTCAATCGTTCTCGTATT 
Type IVc R TCGTTGTCATTTAATTCTGAACT 
Type IVd F AATTCACCCGTACCTGAGAA 
Type IVd R AGAATGTGGTTATAAGATAGCTA 
Type IVh F TTCCTCGTTTTTTCTGAACG 
Type IVh R CAAACACTGATATTGTGTCG 
Type V F GAACATTGTTACTTAAATGAGCG 
Type V R TGAAAGTTGTACCCTTGACACC 











Table 4.1 (continued). 
Experiment Primer name Sequence (5’ to 3’) Reference 
Multilocus 
sequence typing 
arcC-Up TTGATTCACCAGCGCGTATTGTC Enright et al.(103) 
 arcC-Dn AGGTATCTGCTTCAATCAGCG  
 aroE-Up ATCGGAAATCCTATTTCACATTC  
 aroE-Dn GGTGTTGTATTAATAACGATAT  
 glpF-Up CTAGGAACTGCAATCTTAATCC  
 glpF-Dn TGGTAAAATCGCATGTCCAATTC  
 gmk-Up ATCGTTTTATCAGGACCATC  
 gmk-Dn TCATTAACTACAACGTAATCGTA  
 pta-Up GTTAAAATCGTATTACCTGAAGG  
 pta-Dn GACCCTTTTGTTGAAAAGCTTAA  
 tpi-Up TCGTTCATTCTGAACGTCGTGAA  
 tpi-Dn TTTGCACCTTCTAACAATTGTAC  
 yqiL-Up CAGCATACAGGACACCTATTGGC  
 yqiL-Dn CGTTGAGGAATCGATACTGGAAC  
PCR of PVL  luk-PV-F ATCATTAGGTAAAATGTCTGGACATGATCCA  
 luk-PV-R GCATCAACTGTATTGGATAGCAAAAGC  
PCR of hlg hlg-F GCCAATCCGTTATTAGAAAATGC  
 hlg-R CCATAGACGTAGCAACGGAT  
PCR of mecA mecA-F AAAATCGATGGTAAAGGTTGGC  
 
 





Table 4.2  
Demographic characteristics of patients with MRSA bacteremia 
Characteristics N (valid %) 
Gender  
Male 16 (55.2) 
Female 14 (44.8) 
Age ≥ 65 years 11 (39.3) 
Race  
Caucasian 14 (48.3) 
African American 15 (53.5) 
Other 0 (0) 
Service in First 48 hours  
Intensive care unit 11 (37.9) 
Other 18 (62.1) 
Comorbidities  
Diabetes mellitus 15 (51.7) 
Chronic skin condition 4 (13.8) 
Chronic kidney disease 12 (41.4) 
Chronic heart failure 8 (26.7) 
Obesity 11 (36.7) 
BMI ≥ 30 11 (36.7) 
Immunosuppression 2 (6.9) 
HIV 3 (12) 
Invasive procedures  
Surgery 3 (10.3) 
Dialysis 6 (20.7) 
Intravenous catheter 8 (26.7) 
Mechanical ventilation 3 (10.3) 
History  
Smoking 11 (37.9) 
Injection drugs 1 (3.4) 
Hospitalization 12 (41.4) 
Prior antibiotic usage 21 (72.4) 
Long term care facility 6 (20.7) 
Source of bacteremia  
Pneumonia 10 (35.7) 
Osteomyelitis 5 (17.8) 
Dialysis catheter and fistula related infection 4 (14.3) 
Cellulitis 4 (14.3) 
Central line infection 3 (10.7) 
Septic arthritis 1 (3.6) 




Table 4.3  
Percentage of PVL, mecA and hlg virulence factors of isolates belonging to each 
combination type (PFGE-MLST-SCCmec) 
 
Combination types Presence or absence of virulence factors 
 PVL mecA Hlg 
 + − + − + − 
100-ST5-II 7% 17% 23% - 23% - 
300-ST8-II 3% - 3% - 3% - 
300-ST8-IV 33% - 33% - 33% - 
300-ST100-IV 3% - 3% - 3% - 
700-ST72-IV 10% 7% 17% - 17% - 
700-Novel-IV - 3% 3% - 3% - 
800-ST5-II 3% - 3% - 3% - 
800-ST5-IV 3% 7% 10% - 10% - 
Novel-ST5-V 3% - 3% - 3% - 
 
Table 4.4  
Number of isolates possessing different MIC for vancomycin 
Vancomycin MIC (µg/ml) Number of isolates (%) 
0.5 13 (43.3%) 
1 7 (23.3%) 
1.5 5 (16.6%) 











Univariate (crude) analysis of the association between risk factors and MRSA isolates 
with MIC >1 µg/mL for vancomycin 
 
Variables 





Service in first 48 hours 1 
Diabetes mellitus 0.42 
Chronic kidney disease 0.23 




Mechanical ventilation 1 
HIV 1 
Use of injection drug 0.31 
Smoking 0.09 
Prior antibiotic use 0.03** 
Prior Hospitalization 0.1* 
Prior surgery 1 
Long term care facility 0.33 
Dialysis 0.33 
Intra-venous catheter 0.2 
Nursing home 0.07* 
Positive MRSA culture 0.2 
Positive nasal swab 0.28 
Presence of PVL  0.01** 
Presence of HLG 0.33 
SCCmec type 0.47 
Clonal type 0.38 
MLST type 0.27 
 
 







STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF MsaB PROTEIN 
Introduction 
The msaABCR operon has been described to be consisting of four genes namely 
msaA, msaB, msaC, and an antisense RNA msaR. Of these, msaA and msaC were found 
to be non-coding RNA and only effector protein was found to be encoded by msaB (56). 
The MsaB protein is believed to execute the regulatory function of the msaABCR operon 
through its interaction with global regulators such as sarA, agr, sigB, and other genes.  
MsaB protein (previously called CspA) is predicted to contain a cold shock DNA binding 
domain (CSD) and bears homology to E. coli and B. subtilis cold shock proteins (CSPs).  
Bacteria respond to abrupt decrease in temperature by changing the protein expression 
patterns (21). Although expression of most cellular proteins decrease during the cold 
stress, expression of cold shock proteins reaches its peak at this time. One of the first 
proteins described to express under cold shock is the E. coli cold shock protein CspA 
(22). Many more proteins have been discover afterwards, possessing homology to the 
E.coli CspA protein. This includes Bacillus subtilis proteins CspB, CspC, and CspD 
(122). Sequence alignment of CSPs from several different organisms revealed that they 
possess a significant sequence homology with eukaryotic gene regulatory Y-box factors. 
Y-box proteins are DNA binding proteins are known to regulate transcription and 
translation (123). Although most CSPs are found to be expressed during cold shock, 
CspE and CspC are found to express constitutively at normal growth conditions at 37°C. 
Moreover, the constitutively expressed CSPs were thought to be regulating two major 




three CSP family proteins. All of them bears significant homology to the E. coli CspA. 
Katzif et al in their studies have suggested that the S. aureus CspA (or MsaB) is involved 
in the regulation of pigment production and susceptibility to antimicrobial peptide of 
human cathepsin-G (124, 125).  The ability of S. aureus to cause a wide array of 
infections is due to its ability to evade or defend itself from host immune system (126). 
During Invasion, S. aureus has the ability to sustain the response triggered by the host, 
including the harmful reactive oxygen species (ROS) produced by neutrophils and 
macrophages, which are key cells of the human innate immune system. A study by Liu et 
al suggested that the golden pigment produced by S. aureus, called staphyloxanthin plays 
a significant role in susceptibility of S. aureus to reactive oxygen species (ROS) and 
neutrophil killing (127). In that study, the ∆crtMN mutants that is deficient in pigment 
production was found to be more susceptible to killing by ROS and by neutrophil 
phagocytosis. Therefore MsaB could be indirectly or directly linked to the immune 
evasion processes during stressed conditions. Moreover, MsaB has also been found to be 
playing significant role in biofilm formation, antibiotic resistance, small colony variance 
formation, and capsule formation. These are thought to be the basis for S. aureus long 
term survival and persistence inside the host. Sahukhal et al suggested that the 
∆msaABCR operon mutant of the community–acquired MRSA strain USA300 is 
defective in biofilm formation (128). In an unpublished study, I observed that whereas 
wild type S. aureus strain Mu50 is able to produce small colony variants, the msaABCR 
mutant of it is unable to produce small colonies. These observations indicate that 
msaABCR mutant may be defective in the stress response regulation. As mentioned 
before, MsaB is found to be the only protein produced from the msaABCR operon, this 
 
 
suggests that MsaB may be responsible for stress response regulation in 
study, we expressed and purified MsaB protein and characterized the structure and its 
role in responding to stress 
Cloning, expression, and purification
The msaB open reading frame
pH6HTNHis6HaloTag® T
ApaI fragment. The resulting plasmid pH6HTN
BL21-DE3 strain and transformants were selected in LB
overnight culture of a positive col
µg/ml ampicillin.  
Figure 5.1. Plasmid map of pH6HTN His
When the cells reach OD
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conditions. 
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with protease inhibitor cocktail (Roche), and lysed by sonication. Cell lysate was then 
centrifuged at 10,000 ×g for 30 minutes to remove cell debris.  
The His6Halo-MsaB fusion protein was purified from the clear lysate using a 
nickel column (HisPur
TM
 Ni-NTA resin, Thermo Scientific, Rockford, IL). The fusion 
protein was eluted from the column with phosphate buffered saline supplemented with 
250 mM imidazole. Imidazole was removed from the protein sample by dialyzing it 
against pure PBS for overnight. The fusion protein was then cleaved using tobacco etch 
virus (TEV) protease (AcTEV Plus, Life Technologies) to remove the His6Halo tag. 1 
unit of the enzyme was used for 10 µg of protein. 20% glycerol was added to the 
cleavage reaction to stabilize the protein. The cleavage reaction was carried out in 4°C 
for overnight.  
Finally, MsaB protein was purified from the tag using reversed phase HPLC. A 
C-18 column was used for HPLC. The column was first activated by washing with 100% 
acetonitrile (Acn) supplemented with 0.01% trifluoroacetotic acid (TFA). After 
equilibrating the column with 100% H2O supplemented with 0.01% TFA, sample (1 ml) 
was applied to the column at a rate of 1 ml/minute. The column was then washed/eluted 
with a gradient of acetonitrile as follows: 0 – 2% Acn in 2 mins; 2 – 30% in next 2 mins; 
30 – 70% Acn in next 12 mins; 70 – 100% Acn for next 2 mins, and finally, 100% acn for 
2 mins. 1 ml fractions were collected throughout the process. Fractions that showed sharp 
peaks at 280 nm were collected and analyzed by polyacrylamide gel electrophoresis. 
MsaB fraction was determined by molecular weight and mass–spectrometry. After 
removal of acetonitrile from the correct fraction by vacuum centrifuging, the protein was 




Antibody against MsaB was raised in rabbit using a commercial source (Pierce 
Biotechnologies, USA). A 70 – Day bleed of the animals immunized with MsaB was 
purified by column chromatography to isolate pure anti–MsaB antibody. 
Circular Dichroism of MsaB 
Far-UV CD spectra of MsaB were collected on a Jasco J-815 CD spectro-
polarimeter using a 0.1 mm path length quartz cuvette (Precision cell). The samples were 
monitored in a continuous scan mode from 260 to 198 nm with a scanning speed of 50 
nm/min, with a data integration time of 8 s and with 1 nm bandwidth, while the data pitch 
was maintained at 0.1 nm. For each data set, 12 scans were averaged and were subjected 
to buffer subtraction. The buffer-corrected scans were then smoothened using the 
Savitzky-Golay algorithm with the convolution width of 25 using the Jasco spectrum 
analysis program. 
Matrix–Assisted Laser Desorption/Ionization — Time of Flight (MALDI-ToF) analysis of 
MsaB 
The MsaB protein sample was analyzed using MALDI-ToF mass spectrometer 
(Bruker Daltonics Inc). The sample containing 40 picomoles of MsaB (1 µL) was mixed 
with 1 µL of matrix made of 10 mg sinnapinic acid (SA) dissolved in 1:1 acetonitrile: 
water and 0.1% TFA. A 1 µL aliquot of this mixture was then spotted in triplicates on to 
a MSP 96 microchip target (Bruker) and was air-dried. The sample was then analyzed on 
the mass spectrometer with a laser intensity and detector gain kept constant at 60% laser 
and 3x, respectively.  The raw spectra were exported as an ‘.ascii’ file and plotted using 





Western blot of MsaB  
To measure the expression level of MsaB across the growth phases, quantitative 
western blot was performed with whole cell lysates. Overnight cultures were normalized 
to OD600= 0.05 and incubated at 37°C. Cells were harvested at OD600 = 0.7 (early), 1.5 
(mid), 4.0 (late) and overnight (Post) points and frozen until used. Pellets were 
resuspended in PBS with protease inhibitor and lysed by bead beating. Crude lysates 
were centrifuged to remove the cell debris. Clear supernatants were collected and protein 
concentrations in them were determined by BCA method using PierceTM BCA protein 
assay kit (Life technologies, Grand Island, USA). 25 µg of proteins from each sample 
was loaded in SDS-Polyacrylamide gel and separated. After proteins were blotted to a 
PVDF membrane, and blocked by 5% non-fat skim milk, MsaB was detected by anti-
MsaB antibody and peroxidase conjugated secondary antibody. MsaB bands were 
quantified in ImageJ software (67). 
Stress Survival Assay 
 Survival capability of S. aureus during stress conditions was measured by 
enumerating the colony-forming units (CFUs) in different stress conditions. Briefly, 
overnight cultures were normalized to OD600= 0.05 and incubated at 37°C in TSB for 2 
hours. Cells were collected by centrifugation and the spent media was discarded. Cells 
were then resuspended in either plain TSB as a control, or stress conditions such as, low 
pH (5.5), Saline condition (100 mM NaCl), and oxidative stress (10 mM H2O2). Cells 
were then incubated at 37°C. A sample of the cultures were collected every two hours, 
serially diluted, and spread on plain TSA plates. Next day, colonies were counted and 




RNA extraction, reverse transcription, and qRT-PCR 
An aliquot of an overnight culture was normalized to OD600 = 0.05 and grown to 
exponential phase. At this time, cells were subjected to either plain TSB or stress 
conditions such as, low pH (pH 5.0); saline stress; or 10 mM H2O2. Cells were grown for 
1 h and harvested by centrifugation. The bacterial pellet was treated with RNAprotect
TM 
 
Bacteria Reagent (Qiagen, Valencia, CA, USA) and stored at −80°C until used. RNA 
from the cell pellet was isolated using the RNeasy
®
 mini kit (Qiagen) and dissolved in 
DEPC-treated H2O. RNA quality was analyzed by determining the A260/280 ratio using a 
nanodrop spectrophotometer (Thermo). Reverse transcription was carried out from 1000 
ng of RNA using the iScript
TM
 cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, 
USA) according to the manufacturer’s instructions.  Real-time PCRs were performed in 
triplicate using the primers listed in table 5.1. The fold change in gene expression was 
calculated using the formula 2
-∆∆ct  
(68), using the gyrA gene as an internal control. Fold 
change values were statistically analyzed by the independent sample t test using 
GraphPad prism software. 
Results 
MsaB exists as a dimer in solution 
 Recombinant His6Halo-MsaB protein was purified by Nickel column using 250 
mM imidazole as eluting agent. Upon analysis by PAGE, this protein appeared as a 42 
kDa protein. Upon cleavage by TEV protease, a bigger fragment of 35 kDa and a smaller 
fragment of 15 kDa appeared in gel (Figure 5.2 A). Albeit in a very low quantity, the 
original 42 kDa protein also was found in the gel. The 35 kDa protein was predicted to be 




The smaller band was expected to be MsaB, however its molecular weight appeared to be 
exactly twice as much (15 kDa) as the predicted molecular weight of MsaB (7.5 kDa). 
This band was excised and analyzed by mass-spectrometry using a commercial source. 
Indeed, this protein was identified to be MsaB. To my surprise, MsaB appeared in gel as 
a dimeric protein, and was found to be resistant to boiling and detergent treatment. 
Therefore I hypothesized that MsaB exists as a dimer in solution. In HPLC 
chromatogram, fractions 7–8; 11; and 14–15 showed sharp peaks at 280 nm (Figure 5.2 
B). These fractions were collected and analyzed in PAGE. Among these, Fraction 11 was 
found to be the 15 kDa protein, hence MsaB (Figure 5.2 C, D). After removal of 
acetonitrile removal, MsaB was dissolved in 25 mM Tris-HCl buffer, pH 7.4. As 
mentioned before, msaB ORF was cloned into the expression vector 
pH6HTNHis6HaloTag® T7 plasmid, which has a TEV protease cleavage site between the 
tag sequence and the msaB sequence. However, even after cleavage, MsaB carries over a 
small remnant of the vector sequence, which makes the molecular weight of recombinant 
MsaB precisely to be 9.2 kDa. Indeed, MALDI-ToF spectrum for MsaB revealed a peak 
at 9218.69 Da, which corresponds to the monomeric MsaB.  However MALDI-ToF also 
revealed multiple peaks at 18447.85, 27643.53, and 36771.02 Da correspond to dimeric, 
trimeric, and tetrameric MsaB protein, respectively (Figure 5.2 E). The decreasing 
intensities of the multimeric peaks is likely due to the diminished ability of the higher 
order multimers to fly from the matrix.  These peaks corresponding to multimers may 
also indicate that they are non-covalent oligomers of MsaB as indicated by the SDS-
PAGE analysis. However, since dimer was found to be the only visible species in 




solution, however monomeric, trimeric, and tetrameric species can also exist although in 
a very low quantities.  
 
Figure 5.2. Expression, purification, cleavage, HPLC purification and MALDI-ToF 
analysis of MsaB protein: PAGE (A & C), Western blot (D), and MALDI-ToF (E) 





MsaB consists of predominantly α – helical conformation in solution 
The secondary structure of recombinant MsaB was analyzed using far-UV 
circular dichroism (CD). The spectrum showed that the protein adopted a α-helical 
conformation with a signature negative minimum at 208 nm and a shoulder at 222 nm 
(Figure 5.3). Given the expected transcriptional regulator activity of MsaB, it is not 
surprising to observe this conformation, as most DNA binding protein regulators form α-
helix, as they bind and regulate gene expression via the classical helix-turn-helix motif 
(129, 130).  
 
Figure 5.3.  Circular Dichroism spectrum reveals that MsaB adopts an alpha-helical 
structure in solution. 
MsaB exists as a dimer in vivo and its expression is temporally regulated 
 Our results of analysis of MsaB in solution suggest that MsaB perhaps exists as a 
dimeric species. However, whether this was an effect of a reagent or any artificial 
condition on MsaB’s structure, was not clear. To eliminate this possibility, I examined 
the molecular weight of MsaB from whole cell lysates of two S. aureus strains – Mu50 
and UAMS-1 by western blot using anti-MsaB antibody throughout the different phases 
of growth. Western blot of the MsaB protein in the early, mid, late, and post–exponential 
 
 
phases of growth revealed that MsaB
4.4). Western blot also suggests that although MsaB
in both Mu50 and UAMS
in the late and post phases of growth compared to the early phases
Figure 5.4. Western blot of MsaB at different growth phases in Mu50 and UAMS
Expression of msaB is up
 As hypothesized before, that MsaB, being a CspA family protein may be involved 
in stress regulation in S. aureus. 
to stress conditions revealed that the expression o
oxidative stress (H2O2), 4.5 fold in vancomycin stress, and 3 fold in low pH. However in 
saline stress, no change in expression of 
MsaB may indeed be involved in stress response regulation in 
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Figure 5.5. RT-qPCR revealed that msaB is upregulated during stress condition. 
msaABCR mutant has altered expression of RNA – polymearase subunits 
 I previously reported that Sigma B (σ
B
), which is an important component of S. 
aureus RNA polymersase, is down-regulated in the msaABCR mutant of the VISA strain 
Mu50 (131).  
 





Similar observation was also done by others (56) in the strain USA300 LAC. RNA 
polymerases have been known to be responsible for altering global expression of genes 
during stress conditions (23, 132). It has been reported that cold shock family protein 
CspC regulates an RNA polymerase subunit RpoS in E. coli to regulate stress response 
(23). Moreover from bioinformatic prediction analysis performed in the web based tool 
STRING (http://string-db.org/), MsaB was found to be closely linked to RpoA, RpoB, 
RpoC, RpoZ, and SigmaB (Figure 5.6). Hence I tested the transcription level of rpoA, 
rpoB, rpoC, and rpoZ in wild type and msaABCR mutants, in both plain and stress 
conditions. qRT-PCR analysis revealed that wild type and msaABCR mutant has 
drastically different expression pattern of rpo genes. For instance, rpoZ is severely 
downregulated in saline stress in the mutant, whereas its expression is unchanged in the 
wild type. Also, rpoA is drastically downregulated in low pH in the wild type, but 
relatively unchanged in the mutant. Moreover rpoB, rpoC, and rpoZ are all upregulated in 
both oxidative stress and vancomycin stress, however they are relatively unresponsive to 





Figure 5.7. qRT-PCR of rpo genes revealed a differential expression pattern between the 







MsaB, being a cold shock family protein, was hypothesized to be a stress 
response regulator protein in S. aureus. In this part of my study, I investigated the 
molecular structure of MsaB protein and its possible role of MsaB in stress response 
regulation. To my knowledge this is the first study to systematically characterize the 
structure and function of MsaB protein in S. aureus. Biophysical analysis of MsaB and 
polyacrylamide gel electrophoresis revealed that it exists primarily as dimeric species in 
solution. The reason for the multimeric nature of the MsaB protein is not clear at the 
moment. Most DNA binding proteins have been found to dimerize at the binding site, 
however they usually do not produce dimer in solution (133). MsaB was found to 
produce a strong dimer which is resistant to SDS denaturation. The reason behind this is 
also unclear and experiments are underway to investigate this phenomenon. Another 
interesting fact that was revealed in the biophysical analysis is that MsaB has a 
predominantly α-helical structure in solution. This is contrasting to most of the cold 
shock family proteins that are composed of mostly anti-parallel β-sheets. Three – 
dimensional structure of E. coli CspA, Bacillus subtilis–, B. caldolyticus–, and 
Thermotoga maritime– CspB all revealed presence of five anti-parallel β-strands that 
form a β-barrel (134). Moreover many other proteins that carry cold shock domains 
possess the same β-barrel structure. The eukaryotic Y-box proteins, that also contain this 
barrel structure has also been shown to be DNA/RNA binding protein. Many of these 
cold shock proteins bind to single stranded DNA (ssDNA) or RNA (ssRNA). The only 
exception is eukaryotic Clah8, which can bind to double-stranded DNA (dsDNA). In a 




dsDNA and consequently regulates the transcription of the target gene. This data suggests 
that MsaB also has dsDNA binding properties like eukaryotic Clah8 protein. Our 
observation of MsaB possessing predominantly α-helix suggests that MsaB may be a 
member of helix-turn-helix DNA binding protein family rather than conventional β-barrel 
possessing cold shock proteins. Later in this study, MsaB protein was also found to be 
involved in stress response in S. aureus. msaB gene was found to be upregulated in all 
tested stress conditions except saline. This suggests msaB may be an essential gene to 
regulate transcription of other genes during the stress. Cold shock proteins are known to 
regulate sigma factors. In the chapter II, in my study with vancomycin resistance, it was 
found that sigma B gene was significantly down-regulated in the msaABCR mutant of 
VISA strain Mu50. Also, our observation of alteration in expression of rpo genes suggest 
that MsaB might be regulating the transcription of the RNA polymerase subunits 
including sigma factors to modulate global gene expression in S. aureus. Further 
investigation such as chromatin immune-precipitation (ChIP) coupled with high 
throughput sequencing (ChIP-Seq) using anti MsaB antibody, is currently being carried 
out to unravel which promoters MsaB binds to, in a global level to prepare the cells for 
survival during stress conditions such as the presence of antibiotic, peroxide, or low pH. 
Our earlier observations of defective biofilm, defective capsule, and defective antibiotic 
resistance in the msaABCR mutant may all be the result of absence of regulation of RNA 
polymerases by MsaB protein during these stress conditions. However more detailed 
investigations are required to pinpoint the role of MsaB protein in survival during the 






Primers used in this study 
Experiment Primer name Sequence (5’ to 3’) 
qRT-PCR msaB RT F CGTATTCGTACATTTTTCAGCAA 
msaB RT R CGGTCGCCTTCAACTACTTC 
rpoA RT F AATTGGTGTAATCCCTGTTG 
rpoA RT R ACCATTAGTCCAAACATCCA 
rpoB RT F AAACAGCGAAGTGTTTGAAT 
rpoB RT R GTACGACCTTCATCATCGTT 
rpoC RT F CGCGACTGAAAGCTACTTAT 
rpoC RT R GAACCATAACCTCAACGTGT 
rpoZ RT F AAATTGATGAACAACCTGAAA 
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